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Abstract 
 
These studies combined a variety of molecular biology approaches to 
further identify novel functions of the universal stress sensor, p53. The first study 
describes a novel genetic model system to address the effects of p53 dosage in 
an in vivo context. By developing an allelic series through multiple genetic 
crosses, I obtained mice with incrementally increasing levels of constitutively 
active p53. I describe how p53 dosage results in differential physiological 
outcomes with respect to lifespan, fertility, cell morphology and chromatin 
structure. Furthermore, I identified novel transcripts of p53 that would encode for 
isoforms with the potential to alter p53 stability and localization. These findings 
lead me to propose that p53 has the ability to integrate mechanical stimuli into 
changes in gene expression. In response to mechanical stimuli, p53 may alter 
components of the extracellular matrix and chromatin. This change in the spatial 
organization of the nucleus may be an additional mechanism by which p53 
promotes changes in gene expression patterns.  
In the second study, I identified novel components of a tumor suppressor 
pathway with an alternative approach to analyze RNA sequencing data called 
Annotation Independent Transcriptome Assembly. Using this approach to 
interrogate the transcriptome of p53+/+ and p53-/- mouse embryonic fibroblasts 
(MEFs), I identified Mmergln-int among the top genomic loci differentially 
expressed between p53+/+ and p53 -/- cells. Mmergln-int is a murine 
  vi 
endogenous retrovirus that is transcriptionally upregulated in response to cellular 
stress and regulated by a highly conserved p53 response element in the LTR. 
When overexpressed, the envelope of Mmergln-int is sufficient to decrease cell 
viability. Interestingly, this envelope is present in the genomes of multiple 
vertebrate species and shares a high degree of homology with the exogenous 
virus HTLV-1. I observe the upregulation of human endogenous retroviral 
envelopes in response to p53 activation. I hypothesize that the expression of 
endogenous retroviruses may serve as a marker of oncogenic stress in prostate 
cancer with diagnostic potential. Furthermore, endogenous retroviruses may 
serve as a link between cancer initiation and the activation of an immune 
response to eliminate precancerous cells. 
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Chapter 1: Introduction 
 
Transcriptional Regulation  
The central dogma of molecular biology states genetic information flows 
from DNA to RNA to protein (1). It is estimated that the human genome contains 
between 20,000–25,000 protein-coding genes, however only a fraction of these 
are transcribed at a given time in each cell (2). Transcription, the synthesis of 
mRNA from a DNA template, is under tight regulation to ensure correct 
expression of genes during each phase of the cell cycle, stage of differentiation 
and environmental condition that is imposed on the cell. Transcriptional 
regulation occurs at three interconnected levels: the DNA sequence, chromatin 
structure and through the spatial organization of the nucleus. 
 
Transcriptional Regulation at the Level of the DNA Sequence  
The best-studied mode of transcriptional regulation occurs at the level of 
the DNA molecule. DNA is bound in a sequence specific manner by transcription 
factors. Transcription factors are multimeric proteins that contain a DNA binding 
domain. In eukaryotes, a variety of motifs recognize DNA, such as 
homeodomains, zinc fingers, helix-loop-helix motif or leucine zipper motifs. 
These protein domains physically interact with the DNA by inserting an alpha 
helix in the major groove of the DNA. The sequence that is bound by the 
transcription factor is referred to as the response element. Although the activator 
and repressor regions of transcription factors lack a characteristic structure, they 
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regulate gene expression by enhancing or repressing the binding of the 
transcriptional machinery and chromatin remodelers (3). 
 
Transcriptional Regulation at the Level of Chromatin 
The cells that compose multicellular organisms vary, despite the fact that 
each cell contains a copy of the entire genome within its nucleus. The DNA 
sequence remains relatively stable throughout the life of the cell with the 
exception of mutation, recombination and transposition. This indicates that the 
DNA sequence is not the sole regulator of gene expression. There must an 
additional mechanism that provides a memory of how a gene is transcriptionally 
regulated long after the signal which initiated this event has disappeared. The 
form of gene regulation is epigenetic, and occurs at the level of chromatin (Figure 
1) (4).  
The accessibility of DNA to serve as a template for transcription provides 
another level to regulate gene expression. The DNA molecule is not naked within 
the nucleus. DNA associates with proteins to create a compact, higher order 
three-dimensional structure. If one were to unravel the DNA of a human cell, its 
length would measure about 2 meters. The DNA must fit into a nucleus with a 
diameter of approximately 10µm. Chromatin, the complex of DNA and proteins 
makes this extraordinary feat possible (3). 
The structure of chromatin is compacted highly compact. The basic unit of 
chromatin, the nucleosome is analogous to a spool of thread. An octamer  
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Figure 1. Changes in chromatin structure alter gene expression 
The core histones form nucleosomes, which serve as a ‘spool’ for the DNA 
‘thread’. Histones undergo posttranslational modifications on tails and 
globular domains, which regulate chromatin condensation. Condensed 
chromatin is associated with transcriptional silencing. (from 4) 
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typically containing two of each histo ne protein H2A, H2B, H3 and H4 form the 
cylindrical spool-like structure. At the first level of compaction, precisely 146 
basepairs of the DNA thread winds around the nucleosome 1.65 times. The tails 
formed by the amino terminal extensions of each core histone protein protrude to 
stabilize the DNA wrapped around the octamer. Electron microscopy reveals a 
structure 10 nm in diameter with the appearance of beads on a string. The 10 nm 
fiber can also undergo further compaction by the linker histone H1. Histone H1 
locks the DNA in place and determines the angles at which the DNA enters and 
leaves the nucleosome. This creates a fiber with a 30 nm diameter  (3). The 30 
nm fiber forms large loops which are hypothesized to be organized into distinct 
chromatin domains (5). 
The structure of chromatin directly correlates to its function.  The actively 
transcribed regions of the genome are composed of euchromatin. Euchromatin is 
formed by the 10 and 30 nm chromatin fibers. Their de-condensed structure 
promotes transcription by allowing RNA polymerase and transcription factors 
access to the DNA.  On the contrary, the highly compact heterochromatin is 
associated with low levels of transcription. These regions of the genome are 
deemed transcriptionally silent, because their structure of does not allow DNA to 
be exposed to the factors essential for transcription. Thus, the regulation of 
chromatin structure is essential to the regulation of transcription. Mechanisms to 
modify the structure of chromatin include methylation of DNA and 
posttranslational modifications of histones (6, 7).  
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The posttranslational modification of histones regulates the degree to 
which chromatin is condensed (8, 9). Modifications at amino- and carboxy-
terminal histone tails and histone globular domains include methylation, 
acetylation, phosphorylation, ubiquitylation, sumoylation and ADP-ribosylation. 
Posttranslational modifications target specific histones at distinct amino acids. 
For example the lysine 9 of histone H3 can undergo methylation. Furthermore, 
the degree of methylation can also vary. Histone 3 can be mono-, di- or 
trimethylated at lysine 9 (9). 
Genome wide studies of histone modifications revealed distinct patterns of 
specific modifications at genomic regions such as promoters, enhancers and 
transcribed genes. Posttranslational modifications appear to be associated with 
specific transcriptional states. For example, the methylation of histone 3 lysine 9, 
histone 4 lysine 20 and histone 3 lysine 27 are implicated in heterochromatin 
silencing and tend to be localized in transcriptionally inactive regions of the 
genome. On the contrary, the methylation of histone 3 lysine 4 and histone 
acetylation are highly enriched in active promoters and transcribed genes (10). 
Many models have been proposed to suggest how posttranslational 
modifications alter the condensation of chromatin. It has been hypothesized that 
histone modifications change the net charge of the histones which alters their 
affinity to DNA. Weak DNA-histone interactions promote transcription. 
Additionally, the stability of the condensed chromatin structure may be altered by 
posttranslational modifications that interfere with interactions between adjacent 
histones proteins (10). 
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The posttranslational modifications of histones and DNA methylation 
compose part of a cellular memory system and prevent changes in cell identity. 
Transcriptional activation and repression through the biochemical modification of 
histones or DNA is an epigenetic phenomenon. As development proceeds or 
environmental conditions are altered, patterns of gene expression change and 
the information provided by the initial stimuli may be lost. However, the 
transcriptional state of the gene is maintained despite the loss of the initiating 
signal, due to the epigenetic modifications of DNA and histones (11). 
 
Transcriptional Regulation at the Level of Nuclear Organization  
The nucleus does not simply store the genetic information of the cell. It is 
a highly organized organelle containing numerous subnuclear structures.  Many 
of these nuclear structures are implicated in transcriptional regulation, however 
the molecular mechanisms regulated by these structures remain unknown.  
Numerous studies suggest the higher order organization of the contents of the 
nucleus are nonrandom and it appears the spatial organization of nucleus is an 
additional mechanism by which gene expression can be regulated (12, 13). 
Multiple studies suggest chromosomes inhabit distinct domains within the 
nucleus referred to as chromosome territories. Early research illustrated that the 
centromeres and telomeres of plant chromosomes are located at opposite sides 
of the nucleus (14). Furthermore, ultraviolet irradiation of tiny regions of nucleus 
illustrated that damage to a single site in the interphase nucleus does not result 
in damage throughout the cell. The DNA damage was localized discrete region of 
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the metaphase chromosome, thus chromosomes must be highly compact and 
restricted to distinct domains within the nucleus and this organization is somehow 
maintained among cells within a tissue (15). Finally, studies in Drosophila 
mapping the topography of multiple genomic loci revealed that the positions of 
genes within the nucleus are not random (16). Together, these studies lead to 
the concept of the chromosome territory.  
Technological advances in studying the spatial organization of the nucleus 
is beginning to provide us with clues as to how the nuclear structure influences 
gene function (5). It is now possible to generate an “interactome” with 
technologies such as chromosome conformation capture (3C) or DNA adenine 
methylation identification (DamID) (17). Furthermore, live cell imaging has 
demonstrated genes looping out of their chromosome territory when located in 
domains of constitutively high expression, or upon activation of transcription (18). 
This looping out of chromatin facilitates transcription at distinct sites of the 
nucleus.  
Although we often think of transcription in a linear fashion in which the 
RNA polymerase finds the promoter of a single gene, this is likely not the case. 
Transcription is highly compartmentalized. It can be visualized as discrete foci 
dispersed throughout the nucleus with bromo-UTP, or with antibody staining 
against the RNA polymerases. These hot spots of transcriptional activity are 
deemed transcription factories. It is hypothesized one function of transcription 
factory is to provide an efficient means to transcribe multiple genes at once (19). 
However, it has also been proposed that these transcription factories promote 
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chromosomal interactions through the co-transcription of genes (5). Although the 
precise mechanisms by which this occurs remain poorly understood, interactome 
studies are revealing that the sites chromosome territory intermingling occur 
between DNA sequences that encode the active transcription unit and the 
binding sites for transcriptional activator or repressor. Thus, it appears the 
chromatin loop is comprised of an active transcription unit and its respective 
regulatory motif (17).  
It is not only active transcription that is compartmentalized; the nucleus 
maintains a clear structure for transcriptional repression. First, the orientation of a 
DNA sequence within the chromosome territory relates to its transcriptional 
activity. The nucleus is segregation in gene-rich and gene-poor chromatin 
domains. Transcriptionally silent genomic loci, such as telomeres and 
centromeres, reside at the periphery of the nucleus at the nuclear lamina (5). 
These regions of the genome are composed of repetitive DNA sequences which 
are maintained in a heterochromatic state (20).   
 
Repetitive Elements 
Repetitive elements compose a significant portion of the mammalian 
genome  (21). These genomic regions were once considered ‘junk DNA’ due to 
the fact that they are extremely gene poor. Today it is evident that some 
repetitive elements are actively transcribed noncoding RNAs, however the 
function of most of these transcripts remain largely unknown. Distinct classes of 
repetitive elements are localized to specific regions of the chromosome (Figure 
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2) (20). Although repetitive elements are enriched at centromeres and telomeres, 
they are also distributed throughout the entire mammalian genome, and can be 
visualized as G and R bands on condensed chromosomes (22). Transposons 
such as LTR retrotransposons, LINE elements and SINE elements are classified 
as interspersed repeats. The centromeric region of the chromosome are formed 
by satellite DNA (20).  
 
Repetitive Elements and Stress 
The majority of repetitive sequences in a genome are classified as 
transposable elements. Transposons are present in every domain of life; they are 
present in the genomes of bacteria, archaea and eukarya (23). A transposable 
element is a DNA sequence that can insert itself or copies of itself into a new 
location of the genome. DNA transposons, such as Tc1/mariner, Mutator, 
piggyBac , Maverick,  Sleeping Beauty, move through the genome through a cut 
and paste mechanism and make up 2.8% of  human genome.  
The retrotransposons, which mobilize through a copy and paste mechanism via 
an RNA intermediate are far more abundant. A conservative calculation indicates 
the comprise 42.2% of human genome and include families of repeats such as 
LINEs, SINEs and endogenous retroviruses (24).  
Transposable elements are ubiquitous feature of a genome, which are 
hypothesized to generate genetic diversity in response to stress. Barbra 
McClintock discovered the transposon through her work on Ac/Ds elements in 
maize in during the 1940’s (25). In her 1984 Nobel Prize lecture she 
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Figure 2. Repetitive elements in the mammalian genome 
A schematic representation of a mouse chromosome shows 
repetitive DNA sequences are distributed throughout the entire 
mammalian genome. DNA transposons and subtypes of retro- or 
RNA transposons such as LTR transposons, LINE elements and 
SINE elements are classified as interspersed repeats.  
Heterochromatin composed of major and minor satellites 
compose the pericentromeric and centromeric regions of the 
chromosome, respectively. (from 20) 
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hypothesized that the function of the transposable element is to enhance fitness 
of the organism (26). Since this speech, numerous examples of stress 
responsive transposition have been reported in bacteria and yeast. For example, 
in bacteria, depletion of metabolic small molecules like cAMP lead to Group II 
intron mobilization (27). Furthermore, in yeast a DNA transposon mediates 
mating type switch in response to nutrient depletion. In yeast approximately 30 
DNA damage checkpoint response proteins stimulate Ty1 retrotransposition (23). 
In vertebrates our less is known about the role of stress in transposable 
elements. The mobilization of transposons is highly restricted in higher eukaryotic 
organisms (28). Nonetheless, expression of these elements is frequently 
reported. For example, LINEs are transcriptionally upregulated in response to 
ultraviolet irradiation, gamma irradiation and by selected drugs in human and rat 
(29, 30). Furthermore, numerous studies report that expression of endogenous 
retroviruses, the LTR retrotransposons, in disease states such as cancer, MS 
and lupus (31). The lack of understanding of the function of these elements has 
lead to repetitive sequences being referred to as the dark matter of the genome 
(32).  
 
p53: The Universal Stress Sensor 
The universal stress sensor belongs to a group of highly conserved 
transcription factors of p53/p63/p73 gene family (33). An ancestral gene of 
p53/p63/p73 family first makes an appearance in the early metazoans, 
specifically the sea anemone. Interestingly, the primary function of this ancestral 
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gene is to protect the germ line from genomic instability in response to cellular 
stress. From insects, worms, clams, vertebrates, and humans this function is 
maintained over one billion years of evolution. A common ancestral gene to most 
similar to p63/p73 is present in the genomes of almost all invertebrates. In 
cartilaginous fish, a duplication of the gene p63/p73-like gene occurs which 
produces a gene closely related to the p53. By the time the bony fish emerge 
p53, p63, and p73 exist in the genome, and in higher vertebrates diversification 
of these three transcription factors occurs. It is during this evolutionary period 
that somatic stem cells with the ability to regenerate adult tissues emerge. It is 
p53 that takes on the function of protecting these somatic stem cells and 
progenitor cells from genotoxic stress. Thus, it is first in higher vertebrates that 
p53 acquires structure and the tumor suppressor function for which it is widely 
known today. 
The human p53 gene is located at chromosome 17p13.1. It is 19,198 
nucleotides in length from exon 1 to exon 11. Transcription of the full length 
isoform begins in the second exon and ends in the 11th exon. This encodes a 
393 amino acid protein with a well characterized structure (Figure 3). From 
residues one to 61 contain starting from the amino terminus, is the 
transactivation domain (TAD) that is further divided into TAD and TAD2. 
Residues 22 and 23 critical in this domain because negative regulator of p53, 
MDM-2, binds there to block transcription and promote the ubiquiniation of the 
carboxy-terminal domain to promote its degdration (34) and ubiquitinates lysine 
residues in the carboxy-terminal domain region (35). The TAD is followed by a 
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TAD 1 
TAD 2  
PxxP 
DNA Binding Domain NLS OD BR 
 1      42                         96                                                                                    286  299      315  319    350  362       390   
Figure 3. The domains of the p53 protein 
The tumor suppressor, p53 contains multiple domains with well 
characterized functions. In murine p53, two amino terminal 
transactivation domains (TAD 1 and TAD 2) are followed by a 
proline rich region (PxxP). This region, as well as the carboxyl-
terminal domain is critical for the negative regulation of p53. The 
carboxyl-terminal domain is composed by nuclear localization 
signal (NLS), oligomerization domain (OD) and basic region 
(BR). The best established function of p53 is its function as a 
transcription factor. The oligomerization domain promotes the 
formation of tetrameric structure which can bind DNA is a 
sequence specific manner via the DNA binding domain. 
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proline‐ rich domain (PRR) at residues 61–94, and this region of the 
protein is involved in apoptosis (36). Residues 102–292 are critical to the function 
of p53 as a transcription factor. This region comprises the DNA-binding domain, 
and is a hotspot for mutations in cancer. The DNA-binding domain recognizes 
the p53 response (p53 RE), a specific sequence in or near introns of genes 
which are regulated by p53 (37). This general sequence of the p53 RE is 
RRRCWWGYYY, where R=A or G, W= A or T and Y=C or T. This 
RRRCWWGYYY sequence is repeated twice; the prototype p53 RE is comprised 
of two decameric motifs referred to as half sites. The half sites are separated by 
a spacer of 0-13 nucleotides. 
Like many transcription factors, the p53 protein functions as a multimeric 
protein. An oligomerization domain (OD) spans amino acid residues 324–355 to 
enable the formation of a tetramer, the structure which has the capacity to bind 
DNA in a sequence specific manner (38). The OD is followed by the carboxy-
terminal domain (CTD) at residues 356–393. This CTD regulates DNA binding 
activity and protein stability (39). The amino-terminus and carboxy-terminus of 
p53 are alternatively spliced to produce distinct isoforms with a diverse functions  
(40).  
As previously mentioned, the best established role of p53 is its function as 
a transcription factor. In response to stress, the p53 protein is stabilized by a 
variety of posttranslational modifications that can influence the specificity of the 
promoter bound by the transcription factor (41). Direct targets of p53 regulation 
are identified by the presence a p53 RE, which is bound by the p53 tetramer 
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(37). Subtle changes to this sequence alter the affinity of p53 binding, which 
influences the expression of each individual p53 target gene. Furthermore, the 
subset of p53 target genes that are activated during a given stress stimulus are 
also influenced by tissue specific co-activators and co-repressors recruited by 
p53 (42). These proteins work together to alter the epigenetic landscape of the 
target gene promoter and recruit the transcription machinery. Decades of 
extensive research provide insight in how these factors converge to promote 
discrete cellular outcomes in order to maintain the integrity of the genome.   
Since p53 acts as a transcriptional activator of genes in response to 
cellular stress, it is intriguing to speculate if this master regulator potentially 
controls the expression of repetitive elements. Furthermore, is it possible these 
genomic elements could contribute to p53’s tumor suppressor function. Although 
the identification of p53 target genes remains a mainstay in cancer research, the 
role of p53 in regulating repetitive regions of the genome remains unknown. 
Advances in high throughput sequencing technology are just now allowing us to 
interrogate the expression of repetitive regions the regions of the genome. 
 
Technological Advances in Detecting Expression of Repetitive Elements   
Recent technological advances in gene expression profiling are providing 
researchers with unprecedented opportunities to interrogate genome functions. 
The development of massively parallel cDNA sequencing, or RNA seq provides a 
more precise knowledge of a transcriptome over traditional hybridization 
techniques such as microarrays. RNA Seq provides researchers single base pair 
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resolution of transcripts with a higher dynamic range of to detect differential gene 
expression. This is achieved through the elimination of background caused by 
non-specific hybridization of probes. But the overall goal of transcriptomics is not 
only to accurately determine differential gene expression, it is also to identify all 
the different of transcripts present, including non-coding RNAs, small RNA, 
isoforms generated by alternative splicing and novel transcripts. This is of 
particular interest when studying cancer transcriptomes, because gene fusion 
transcripts can be generated by chromosomal abnormalities such as 
translocations, insertions, deletions or even chromothripsis, the shattering of 
chromosomes. 
The identification of novel transcripts is difficult with conventional RNA 
Seq analysis methods, because they rely on mapping transcripts to a reference 
genome. Transcripts that do not map uniquely, because they are map to multiple 
genomic loci or are not present in the reference genome, may be randomly 
misaligned to an arbitrary genomic locus or remain unidentified. Thus, a 
transcript which is not present in a reference genome is essentially equivalent to 
a probe missing on a microarray.  Therefore, the development of user-friendly 
tools for annotation independent transcriptome assembly is imperative for a 
better understanding of human disease states such as cancer or aging.     
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Chapter 2: Statement of Thesis 
This thesis combines variety of molecular biology approaches to further 
identify novel functions of the universal stress sensor, p53. The first study 
describes a novel genetic model system to address the effects of p53 dosage in 
an in vivo context. By developing an allelic series through a series of genetic 
crosses, which obtained mice with incrementally increasing levels of 
constitutively active p53. We describe how p53 dosage results in differential 
physiological outcomes with respect to lifespan, fertility, cell morphology and 
chromatin structure. We identify novel transcripts of p53 which would encode for 
isoforms with the potential to alter p53 stability and localization. Our findings lead 
us to propose that p53 has the ability to integrate mechanical stimuli into 
changes in gene expression. In response to mechanical stimuli, p53 may alter 
components of the extracellular matrix and chromatin. This change in the spatial 
organization of the nucleus may be an additional mechanism by which p53 
promotes changes in gene expression patterns.  
In the second study, I demonstrate that it is possible to identify novel 
components of a tumor suppressor pathway with an alternative approach to 
analyze RNA sequencing data called Annotation Independent Transcriptome 
Assembly (AITA). Using this approach to interrogate the transcriptome of p53+/+ 
and p53-/- mouse embryonic fibroblasts (MEFs), I identified Mmergln-int among 
the top genomic loci differentially expressed between p53+/+ and p53-/- cells. 
Mmergln-int is a murine endogenous retrovirus of the family Gammaretroviridae. 
I show how p53 regulates the expression of Mmergln-int, and its expression 
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mediates cell viability. Notably, I identify p53 responsive endogenous retroviral 
components with a striking degree of homology to Mmergln-int in the genomes of 
numerous organisms from zebrafish to humans. In this study I propose a 
potentially a novel and conserved mechanism by that endogenous retroviruses 
contribute to p53 mediated tumor suppression.  
In the chapter Future Directions, I outline a detailed proposal to further 
investigate the role of endogenous retroviruses in tumor suppression. This 
chapter was submitted to the National Cancer Institute as a F32 proposal for the 
PA-11-113, Ruth L. Kirschstein National Research Service Awards for Individual 
Postdoctoral Fellows with a submission date of August 8th, 2013.  
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Chapter 3: An In Vivo Allelic Series to Study the Effects of p53 Dosage 
 
Introduction 
Disruption of the p53 signaling pathway is the most commonly observed 
genetic defect in human cancers (43). P53 functions primarily as a tumor 
suppressor. A plethora of cellular stressors, like DNA damage or oncogene 
induced hyperproliferation, lead to the stabilization the p53 protein (44). P53, in 
turn, acts as a transcription factor to induce the expression of hundreds of 
downstream genes. The expression of these genes suppress tumorigenesis by 
inducing diverse signaling cascades to maintain the integrity of the genome. This 
results in distinct cellular outcomes such as apoptosis, senescence, DNA repair 
or cell cycle arrest. Thus, the concept of restoring p53 activity to tumors with the 
goal of correcting aberrations in these intricate processes is an attractive 
therapeutic option to treat human cancer (45, 46). However, it is not well 
understood how the precise level of p53 expression is essential to its function.   
 Some evidence suggests that differential levels of p53 expression result in 
varying physiological outcomes. One such study knocked down p53 with varying 
degrees of efficiency in hematopoietic stem cells derived from an Eμ Myc mouse 
model, then adoptively transferred the stem cells after sublethal irradiation. 
Interestingly, lymphoma with an increasing degree of severity resulted as the 
efficiently of the p53 knockdown increased (47). A similar effect is also observed 
among the human population. Numerous p53 germline polymorphisms have 
been documented in the human population (48). The clinical outcome of these 
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polymorphisms varies due to the degree of p53 activity that is lost. Whereas 
some mutations result in strong cancer predisposition phenotypes due to a non-
function p53 protein, others result in proteins with limited functional alterations 
and low tumor penetrance (49). Thus, when p53 activity is differentially reduced, 
dramatically different consequences are observed in vivo. 
 Clearly p53 is a powerful tumor suppressor, and loss of p53 function has 
detrimental effects due to the inability of the cell to induce apoptosis, senescence 
and cell cycle arrest in response to a stress stimulus. On the other hand, the 
physiological effects of enhance p53 activity are perplexing. Mouse models with 
accelerated aging phenotypes, such as Terc-/-, Ku80-/- express high levels of p53, 
the aging phenotypes are rescued by a p53-/- background (50-52). Furthermore, 
two p53 hypermorphic mouse models that express either a truncated p53 allele 
or naturally occurring p53 isoform exhibit an accelerated aging phenotype (53, 
54). On the contrary, additional transgenic copies of the p53 gene do not result in 
significant changes in lifespan (55). Thus, a better understanding of the effect of 
differential levels of endogenous p53 activity may provide us with additional 
insight into the function this essential transcription factor.  
 To better understand the physiological outcome of p53 dosage, we 
generated an allelic series that results in incremental increases of the p53 
transcript and protein in vivo. Here we report that increased p53 activity 
correlates with distinct physiological changes, decrease in lifespan and loss of 
fertility. As p53 levels further increase, we see distinct cellular changes 
associated with progeroid cells and the expression of novel p53 isoforms.  
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Results 
 
In vivo modulation of p53 activity through an allelic series 
 To investigate the physiological consequences of varying levels of p53 in 
vivo, we crossed mice harboring a duplication of a 4.3 Mb allele (dp/+) on 
chromosome 4 with mice containing p53 loss of function allele as previously 
described (3, 56). The dp/+ mice bear a duplication on chromosome 4 that is 
syntenous to human 1p36 that results in the constitutive activation of p53 through 
the p16/p19 signaling pathway (Figure 1A) (Bagchi) In order to further manipulate 
p53 levels, mice with and without the dp/+ allele were bred to carry the wildtype 
p53 allele (p53+/+) or be heterozygous (p53+/lsl) or homozygous (p53lsl/lsl) for an 
allele which results in the loss of p53 function through in insertion of a stop codon 
in exon 1 of the p53 gene (Figure 1B ) (45). As expected, E18.5 dp/+ p53lsl/lsl 
mice did not express the p53 transcript (Figure 2A) or protein (Figure 2B). The 
p53 expression level increased in E18.5 dp/+ p53+/lsl and dp/+ mice in 
comparison to p53+/+mice, respectively.  
 Next, we wished to determine if the presence of the dp/+ allele leads to 
the constitutive activation of p53. To this end, we investigated if an increase in 
p53 protein level correlates with an increase in p53 target gene activation. We 
evaluated the transcript levels of Mdm2, p21 and Bax in mouse embryonic 
fibroblasts (MEFs) generated from p53lsl/lsl, p53+/lsl, p53+/+, dp/+ p53+/lsl, dp/+ 
p53+/lsl and dp/+ embryos (Figure 3A).  We observe a significant upregulation of 
these genes in the dp/+ p53+/lsl and dp/+ in comparison to the p53+/+ state. To 
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further validate the constitutive activation of p53 in presence of the dp/+ allele, 
we investigated the stability of Mdm2. Mdm2 is an E3 ubiquitin ligase responsible 
for the degradation of p53 through an autoregulatory feedback loop. The 
phosphorylation of Ser166 stabilizes Mdm2 to regulate p53 activity. In dp/+, 
p53+/+ and dp/+,p53+/lsl mice, we observe higher levels of Mdm2 phosphorlyated 
at Ser166 comparison to p53+/+ MEFs. After observing high levels p21, we 
evaluated the transcript levels of p16 and p19 in MEFs generated from p53lsl/lsl, 
p53+/lsl, p53+/+, dp/+ p53+/lsl, dp/+ p53+/lsl and dp/+ embryos to confirm the 
senescent phenotype (Figure 3A). 
 Since a major function attributed to p53 is cellular senescence, therefore 
we wished to determine if increasing levels of p53 corresponds with an increase 
p21 expression level and decreases in cellular proliferation. In our p53 allelic 
series, we observed that as p53 protein level increased, p21 protein levels 
demonstrated a similar trend (Figure 3C). Furthermore, we observe a distinct 
decrease in cellular proliferation with increasing levels of p53 ex vivo (Figure 4A). 
Thus, with incremental increases in p53, we observed increasing levels of p53 
target gene expression and enhanced p53 function with respect to cellular 
proliferation. 
 The role of p53 as a central regulator of lifespan remains controversial, 
whereas some models with enhanced p53 activity exhibit accelerated aging 
phenotypes other show no significant decrease in lifespan. To better understand 
how p53 contributes to lifespan, we generated Kaplan-Meier survival curves for 
mice of the p53 allelic series which were of the same genetic background and 
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were maintained under identical conditions. We previously reported that dp/+ 
mice exhibit perinatal lethality on p1 (Bagchi). Mice with the dp/+ p53 +/lsl 
genotype demonstrate a reduced median lifespan (125.5 days) compared to 
p53+/+ mice (365 days), p53 +/lsl (214 days) dp/+ p53 lsl/lsl (150 days) and p53 lsl/lsl 
genotype (Figure 4B).  
 
Constitutive activation of p53 results in age-related histopathological lesions in 
vivo 
Although the dp/+ p53 +/lsl mice are viable, the exhibit striking 
histopathological features associated with a premature aging. The most 
prominent trait of the dp/+ p53+/lsl mice is an exaggerated rounding of the back 
that is not observed in other mice of the p53 allelic series. A radiograph detects 
kyphosis by an abnormal convex curvature of the spine of dp/+ p53+/lsl mice 
(Figure 5A, left) but not in p53+/lsl mice (Figure 5A, right). Histopathological 
examination reveals the abnormalities of the thoracic vertebrate of dp/+ p53+/lsl 
mice. Intervertebral discs protrude ventrally and dorsally to focally compress the 
spinal cord (Figure 5B, left) which results in the extreme curvature of the spine 
seen by radiograph. A closer examination of the Intervertebral discs of the dp/+ 
p53+/lsl mice indicates disc degeneration as seen by chondroid metaplasia of the 
nucleus pulposus, fragmentation of disc matrix and necrotic chondrocytes (Figure 
5C, middle, left). Interestingly, we observe an approximate 3-fold upregulation 
transcriptional of mmp9, a matrix metalloproteinase in dp/+ MEFs, a marker of 
early onset disc degeneration in humans (57).  
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In addition to the pronounced curvature of the back, dp/+ p53+/lsl mice 
display precocious changes in tissues associated with aging. By 2 months of 
age, we observe alopecia and loss of whiskers in the dp/+ p53+/lsl mice, but not 
the other mice of the p53 allelic series. This is accompanied by epidermal 
hyperplasia. Furthermore, by histopathological analysis we observe atrophy of 
the male and female reproductive organs. Although mice reach sexual maturity 
by 8 weeks and all dp/+ p53+/lsl mice studied lived past this age, we never 
observed offspring from dp/+ p53+/lsl despite the presence of sperm in the vas 
deferens and ova in the ovaries.   
 
Constitutive activation of p53 induces changes in nuclear morphology associated 
with progeroid cells  
With the goal of further characterizing the effects of enhanced p53 activity, 
we investigated the cellular morphology of MEFS derived from embryos of the 
p53 allelic series. After observing a marked decrease in lifespan and early onset 
of histopathological changes associated with aging, we hypothesized that we 
may observe nuclear abnormalities associated with progeroid syndromes. To 
observe the gross nuclear morphology, we visualized the nuclear lamina of 
p53+/+ and dp/+ MEFs using an antibody against lamin A/C. Cross sections of 
the dp/+ nuclei reveal nuclear blebbing (Figure 6A). One feature of progeroid 
cells are changes in the distribution of trimethylated H3K9 hetrochromatin at the 
nuclear periphery. To asses the distribution of this heterochromatic marker, we 
co-stained the MEFs with H3K9me3 and lamin A/C. In dp/+ MEFs we see de-
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locatization of trimethylated H3K9 heterochromatin in comparison to +/+ MEFs 
(Figure 6B).   
To quantitatively assess the p53 role in the distribution of chromatin at the 
nucleus, we used transmission electron microscopy to measure the average 
number of foci and average thickness of the heterochromatin at the nuclear 
periphery (Figure 7A,B). The heterochromatin at the nuclear periphery of p53+/+, 
p53+/lsl and p53lsl/lsl MEFs dose not demonstrate any statically significant changes 
in thickness with an average thickness of 107.93 ±25.34 nm, 104.71 ±20.64 nm, 
96.82 ±23.64 nm, respectively. Furthermore, the number of heterochromatin foci 
does not vary in number in p53+/+, p53+/lsl and p53lsl/lsl MEFs with an average of 
28.6 ±9.74, 24.9 ±8.60, 27.2 ±6.99 foci per cell, respectively. However in dp/+ 
MEFs we observed profound changes in nuclear architecture. We observed a 
complete loss of heterochromatin foci with only 0.2 ±0.42 foci per cell counted 
(p= 3.12616x10-08). Compared to p53+/+ MEFs, we observed a significant 
reduction of heterochromatin at the nuclear periphery with an average thickness 
of 20.81 ±9.96 nm comparison to p53+/+ MEFs  (p= 7.44x 10-9). Interestingly, this 
defect in nuclear structure is rescued in the absence of p53. We counted an 
average of 28.0±10.88 foci per cell in dp/+ p53lsl/lsl MEFs and obtained an 
average thickness of 106.14 ±23.59 at the nuclear periphery. An intermediate 
phenotype was observed in dp/+ p53lsl/lsl MEFs. The average thickness 
measured 35.91 nm which was a significant reduction when compared to p53+/lsl 
MEFs (p= 6.33x10-08). The average number of foci counted per cell, 11.3 ±5.29, 
was also significant (p= 4.70x 10-4 ). These results taken together demonstrate 
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that as p53 activity increases, loss of heterochromatin at the nuclear periphery 
also increases.  
  
dp/+ MEFs express novel isoforms of p53 
Global increases in the expression isoforms has been observed in aging 
tissues of humans and rodents (58, 59), and p53 isoforms are expressed in aging 
cells (54). Therefore, we wished to investigate what p53 transcripts are 
expressed in dp/+ MEFs that could potentially contribute to the progeroid 
phenotype. To this end, we generated cDNA from dp/+ and p53+/+ MEFs for 
nested RT-PCR. We designed a forward PRC primer in exon 11 which was used 
for each reaction and staggered the reverse primers to amplify exons 1, 4, 8, and 
and 11 (Figure 8A).  In dp/+ MEFs using primers spanning exons 4-11, 8-11 and 
10-11 and 11, we detected PCR products of the expected size were generated 
from +/+ (data not shown) and dp/+ MEFs (Figure 8B, lanes 1-7, top bands lanes 
3 and 6). We subsequently cloned and sequenced the PCR products and 
determined they correspond to the full length p53 transcript. In dp/+ MEFs, we 
detected PCR products smaller then the expected size using primers to span 
exons 8-11 and 11. The cloning and sequencing of the lower PCR bands 
revealed a 721 bp transcript in 18 out of 18 clones (Figure 8B, lanes 3 and 6, 
lower bands). We refer to this transcript as dp/+ p53 isoform 1.   
The mechanisms which generate p53 isoforms include alternative splicing, 
usage of an internal promoters and alternative initiation of translation (60).  
Based on strategic primer design we determined that the transcript of dp/+ p53 
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isoform 1 initiates in exon 8 at nucleotide position 950. To confirm the 
transcriptional start site, we generated a primer in exon 8 upstream of nucleotide 
950 at position 959-970. No lower band was detected suggesting that the 
initiation of transcription occurs via an alternative promoter residing within exon 8 
(Figure 8B, lane 4). Additionally, primers in exons 1 and 4 do not amplify the 
isoform (Figure 8B, lanes 1, 2, and 7). To further validate the presence of this 
transcript, we designed a sequencing primer specific to dp/+ p53 isoform 1. The 
721 bp transcript was detected in cDNA from dp/+ MEFs but not p53+/+ MEFs.  
To confirm our sequencing results which reveal the transcript is alternatively 
spliced at nucleotide positions 1265-1486, we designed a primer which resides 
within the spliced region at position 1270-1292 in exon 11.  This primer does not 
amplify the isoform (Figure 8B, lane 4). The translation of this isoform would 
result in an N-terminal truncation of the p53 protein with alternative CTD (Figure 
9A,B). 
Next, we used a similar nested PCR strategy as described above, but 
staggered the reverse primers to amplify exons 1, 5, 6, and 11 (Figure 10A).  
Using primers spanning exons 1-11, 6-11, 5-11 and 11, we generated PCR 
products of the expected side that were confirmed to contain full length p53 by 
cloned and sequencing (Figure 10B lanes 1-7 upper band). Additional products 
were obtained using primers spanning 5-11 and 6-11 and 1-11 (Figure 10B, 
lanes 3-7, lower bands). From 14 out of 14 clones sequenced, we detected an 
additional p53 isoform we refer to as dp/+ p53 isoform 2. This transcript is 
identical to full length p53 until exon 6 at nucleotide position 708.  The isoform is 
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then alternatively spliced at adding an additional 76 bp of sequence, then 
transcribed in frame at nucleotide position 709-735.  The transcript is spliced 
again at nucleotide position 1412 in exon 11, yielding a 1088 bp transcript we 
named dp/+ p53 isoform 2.  The translation of this isoform would create a C-
terminal truncation of p53 to yield an isoform with an alternative CTD. 
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Figure 4. Modified alleles to modulate p53 dosage 
  
(A) Schematic representation of the duplication (dp/+) and p53 
loss of function allele. The presence of the dp/+ allele yields a 
279 bp band (top left).  
(B) The p53 status was determined by the presence of a 364 bp 
p53 wildtype allele (bottom, top band) and a 278 bp lox stop lox 
allele (lsl).  
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Figure 5. An in vivo murine allelic series of p53 dosage  
 
(A) p53 transcript level was determined in MEFs of the indicated 
genotypes in bar graph. An astrix denotes p>0.005. 
(B) p53 protein level was determined in E18.5 mice of the 
indicated genotypes by western blot.  
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Figure 6. Increasing p53 levels correlates with increasing 
levels of p53 target gene activation and markers of 
senescence 
 
(A) p53 target gene transcript levels were determined in MEFs of 
the indicated genotypes in bar graph. 
(B) Mdm2 phosphoserine 166 level was determined in E18.5 
mice of the indicated genotypes by western blot.  
(C) p21 expression level was determined in E18.5 mice of the 
indicated genotypes by western blot.  
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Figure 7. Increasing p53 levels correspond with decreases 
in cellular proliferation and lifespan 
 
(A) MEFs rates of cellular proliferation  
(B) Kaplan Meier survival curve of mice of the p53 allelic series. 
Dashed line at 50% is the median survival 
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Figure 8. dp/+ p53 lsl/+ mice exhibit kyphosis and intervertebral 
disc degeneration 
  
(A) Radiograph images of p53lsl/+ (left) and dp/+ p53lsl/lsl (right) 
mice. 
(B) Thoracic vertebrae of p53lsl/+ (left) and and dp/+ p53lsl/lsl (right) 
mice. 
(C) Intervertebral discs of p53lsl/+ (left) and and dp/+ p53lsl/lsl  (middle) 
mice. Box with dotted lines depicts enlarged image (left). 
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Figure 9. Constitutive activation of p53 results in nuclear 
abnormalities associated with progeroid syndromes 
 
(A) Midline Z-stack of nuclear envelope of p53+/+ and dp/+ 
MEFs  
(B) Localization of trimethylated H3K9 in p53+/+ and dp/+ MEFs 
 
 35 
 
 
 
0	
5	
10	
15	
20	
25	
30	
35	
dp
/+
	p
53
lsl
/ls
l	
p5
3l
sl/
lsl
	
p5
3+
/ls
l	
p5
3+
/+
	
dp
/+
	p
53
+/
lsl
	
dp
/+
	
Number	of	Foci/Cell	
0	
20	
40	
60	
80	
100	
120	
140	
dp
/+
	p
53
lsl
/ls
l	
p5
3l
sl/
lsl
	
p5
3+
/ls
l	
p5
3+
/+
	
dp
/+
	p
53
+/
lsl
	
dp
/+
	
Heterochroma n	Thickness	
A	
	
	
	
	
	
	
	
	
	
	
	
	
	
B	
Figure 10. Constitutive activation of p53 results in loss of 
heterochromatin 
 
(A) TEM images of p53+/+ and dp/+ MEFs for quantification of 
hetrochromatic foci 
(B) TEM images and quantification of peripheral heterochromatin 
in p53+/+ and dp/+ MEFs 
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Figure 11. Nested RT PCR Detects an N-Terminal Truncated 
Isoform of p53 
  
(A) Nested PCR strategy with to enrich for p53 isoforms.  
Primers flanking exons 1, 4, 8 and 11 were designed to identify 
isoforms of p53 
(B) Nested PCR detects the expression of an alternatively 
spliced isoform of murine p53.  Primers spanning exons 8-11 at 
nucleotide positions 948-1673 (lane 3, bottom band) and 10-11 
(lane 6, bottom band) enrich for a transcript which originates at 
position 950.  This transcript is not detected by using upstream 
primers in exon 8 (lane 4) at nucleotide position 959-970, exon 4 
(lanes 1 and 2) or exon 1.  The transcript is not amplified using 
primer in exon 11 at nucleotide position 1270-1292 (lane 5) but 
can be amplified with an upstream primer at in exon 10 at 
nucleotide position 1246-1267.  The bands and upper bands in 
lanes 1-7 correspond to the full length p53 transcript. 
(C) The dp/+ p53 isoform 1 originates from an internal promoter 
in exon 8 and is alternatively spliced in exon 11. The transcript of 
dp/+ p53 isoform 1 initiates at an alternative promoter within 
exon 8 which results in a 19 bp 5’ truncation of exon 8.  Exon 11 
is alternatively spliced at nucleotide positions 1264-1487 
resulting in a 223 bp truncation of exon 11 
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Figure 12. N-terminal truncation of dp/+ p53 isoform 1 yields 
protein with alternative CTD 
  
(A) Full length p53 contains two transactivation domains (TAD 1, 
TAD 2) one of which contains a proline rich domain (PxxP), a 
DNA binding domain, nuclear localization domain (NLS), 
oligomerization domain (OD) and basic region (BR).  The 
translation of dp/+ p53 isoform 1 results in a protein with a 
truncated amino terminus that contains only the oligomerization 
domain and the basic region 
 (B) The translation of dp/+ p53 isoform 1 generates a protein 
with an alternative CTD  
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Figure 13. Nested RT-PCR Detects a C-Terminal Truncated 
Isoform of Murine p53 
  
(A) Nested PCR strategy with to enrich for p53 isoforms.  
Primers flanking exons 1, 5, 6 and 11 were designed to identify 
isoforms of p53 
 (B) Nested PCR detects an additional alternatively spliced 
isoform of murine p53.  Primers spanning exons 5-11 (lane 3 and 
4, bottom bands) and 6-11 (lane 5 and 6, bottom bands) and 
exons 1-11 (lane 7, bottom band) enrich for a transcript that is 
not detected by using primers enriching for the 3’ end of exon 11 
at nucleotide positions 1433-1454 and 1469-1489 (lanes 1 and 
2).  The bands and upper bands in lanes 1-7 correspond to the 
full length p53 transcript 
(C) The dp/+ p53 isoform 2 is alternatively spliced in exon 6 to 
11. The transcript of dp/+ p53 isoform 1 is alternatively spliced at 
the 3’ end of exon 6 at nucleotide positions 708 which adds 76 
nucleotides of intronic DNA.  The transcript is transcribed from 
nucleotide 709- 735 then spliced again to exon 11 at nucleotide 
position 1412 
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Figure 14. C-terminal truncation of dp/+ p53 isoform 2 yield 
alternative CTD 
  
(A) Full length p53 contains two transactivation domains (TAD 1, 
TAD 2) one of which contains a proline rich domain (PxxP), a 
DNA binding domain, nuclear localization domain (NLS), 
oligomerization domain (OD) and basic region (BR).  The 
translation of dp/+ p53 isoform 2 creates in a protein with a 
truncated carboxyl terminus that contains only half of a DNA 
binding domain region and a deleted NLS, OD and BR  
(B) The translation of dp/+ p53 isoform 1 generates a protein 
with an alternative CTD 
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Primer Position Sequence 
1Ri 158-179 ATGACTGCCATGGAGGAGTCA 
5Ri 641-661 AAGTCACAGCACATGACGGAG 
5Rii 684-702 ATGAGCGCTGCTCCGATGG 
6Ri 713-733 GCTCCTCCCCAGCATCTTATC 
6Rii 764-785 CTGGAAGACAGGCAGACTTTTC 
11Riii 1433-1454 TTACCTTGTAGCTAGGGCTCAG 
11Rviii 1469-1489 AGTGGTTCCTGGCCCAAGTT 
11F 1637-1659 AATGGAAGGAAAGTAGGCCCTG 
 
 
 
 
 
 
 
 
Table 1.  PCR primers for RT Nested PCR to identify dp/+ p53 isoform 1  
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Primer Position Sequence 
1Ri 158-179 ATGACTGCCATGGAGGAGTCA 
5Ri 641-661 AAGTCACAGCACATGACGGAG 
5Rii 684-702 ATGAGCGCTGCTCCGATGG 
6Ri 713-733 GCTCCTCCCCAGCATCTTATC 
6Rii 764-785 CTGGAAGACAGGCAGACTTTTC 
11Riii 1433-1454 TTACCTTGTAGCTAGGGCTCAG 
11Rviii 1469-1489 AGTGGTTCCTGGCCCAAGTT 
11F 1637-1659 AATGGAAGGAAAGTAGGCCCTG 
 
Table 2.  PCR primers for RT Nested PCR to identify dp/+ p53 isoform 2 
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Discussion 
In this article, we report a novel model system to study the effects of 
incremental increases of p53 activity. We hypothesized that with varying degrees 
of p53 expression, we would see distinct phenotypes attributed to differential p53 
dosage. We previously reported that MEFs harboring a duplication of an allele 
syntenous to human 1p36 exhibited elevated levels of p53 (56). Through a series 
of genetic crosses, we obtained mice which harbored the duplication allele in 
combination with either wildtype p53 or heterozygous or homozygous an allele 
which results in p53 loss of function (45). First, we confirmed that the dp/+ p53+/+ 
and dp/+ p53lsl/+ embryos express increasing levels of the p53 protein and 
transcript, respectively. The presence of the dp/+ allele correlated with robust 
upregulation of p21 and Mdm2 phosphorylation of serine 166 in suggesting the 
dp/+ allele results in the constitutive activation of p53. 
Next, we wished to determine if we could identify functions of p53 which 
behave in a dosage dependent manner. To this end, we examined the 
expression of p53 target genes associated with senescence and apoptosis. We 
evaluated the transcript levels of established p53 target genes by p21, Mdm2, 
Bax in MEFs generated from the p53 allelic series. As p53 levels increased, we 
observed increases in p21, Mdm2 and Bax. Dosage dependent behavior of 
apoptosis genes Puma and Noxa was not observed. Our finding may suggest 
that some p53 functions, like senescence, are sensitive to p53 dosage but 
others, such as apoptosis, may function in an on or off manner. To further test 
the consequences of p53 dosage with respect to cellular senescence, we 
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measured rates of cellular proliferation in early passage MEFs. As p53 levels 
increased, rates of cellular proliferation decreased. 
After establishing that incremental increases in p53 dosage correspond 
with an increasing grade of cellular senescence ex vivo, we set out to investigate 
the in vivo repercussions. We hypothesize that one molecular basis of 
organismal aging stems from the accumulation of lesions in the genome. The 
aftermath of these lesions is an increasing basal level of p53. As p53 escalates, 
so does senescence. Stem cells pools in tissues decline and degenerate tissue 
cannot be repaired which eventually leads to the demise of the organism. This 
concept places p53 as a central regulator of aging. 
Our data supports the hypothesis that p53 activity leads to decline a 
reduction in lifespan and tissue homeostasis. The lifespan of dp/+ p53lsl/lsl mice 
does not differ from p53lsl/lsl mice. However, the lifespan of dp/+ p53lsl/+ mice is 
significantly shorter than wildtype mice, suggesting that elevated p53 indeed 
correlates with a shorter lifespan. Furthermore, we observe that elevated p53 is 
also associated with tissue degeneration. Although dp/+ mice die on postnatal 
day 1, perinatal lethality is rescued in dp/+ p53lsl/lsl and dp/+ p53+/lsl mice. Whole 
body histopathology of sex matched littermates subjected to identical 
environmental conditions reveals tissue degeneration in dp/+ p53+/lsl mice but not 
p53+/lsl controls.  
We observe tissue degeneration at multiple sites of the body. The most 
significant lesions are detected in the intervertebral discs. A few recent studies 
support our findings (61, 62). In a progeroid mouse model deficient for the DNA 
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repair endonuclease, ERCC1 defects of the intervertebral discs were observed 
as a result of genotoxic stress post irradiation. A reduction of proteoglycans in 
the intervertebral discs due to upregulation of matrix degrading proteases as well 
as a decrease in the production of new disc matrix contributed to this phenotype. 
It is likely p53 is constitutively activated in this mouse model, and that p53 
contributes to this phenotype. Furthermore, degeneration of male and female 
reproductive tissues and loss of fertility were seen in all dp/+ p53lsl/+ mice. A body 
of literature supports our data demonstrating p53 levels influence reproduction 
(63, 64). 
The decrease in lifespan and early onset of age related tissue 
degeneration observed in the dp/+ p53lsl/+ mouse is characteristic of a segmental 
progeriod phenotype. One of the most striking cellular phenotypes is observed in 
progeroid syndromes such as Hutchinson-Gilford progeria syndrome, Emery–
Dreifuss muscular dystrophy (65). Progeroid fibroblasts exhibit nuclear blebbing 
and gross changes in heterochromatin structure  (66, 67). These changes 
include loss or delocalization of tri-methyated H3K9 heterochromatin  (68).  
Therefore, we decided to investigate the effects of p53 activity on nuclear 
morphology. Single z-stacks through the midline of dp/+ MEFs imaged with an 
antibody against lamin A/C demonstrate abnormal nuclear morphology 
reminiscent of blebbing seen as in some laminopathies. We observe 
delocalization of tri-methyated H3K9 heterochromatin.  
To quantitatively assess how p53 dosage may contribute to the structure 
of perinuclear heterochromatin, we determined the average thickness and 
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number of foci at the nuclear periphery. In dp/+ MEFs we see a profound 
reduction in thickness and essentially no foci are observed. The dp/+ p53lsl/+ 
MEFs show an intermediate phenotype which is completely rescued in dp/+ p53 
p53lsl/lsl MEFs. Thus increasing levels of constitutively activate p53 result in 
nuclear defects of heterochromatin attributed with progeroid syndromes. We 
hypothesized the p53, a key cell cycle regulator may regulate the structure of 
nuclear lamina by inducing its disassembly, and that this may be an underlying 
cause of the nuclear deformities. However, a change in lamin a/c levels or 
phosphorylated lamin a/c was not detected by western blot. The underlying 
mechanism by which p53 dose influences global chromatin structure are yet to 
be determined.   
We know that chromatin changes during aging, and it is intriguing to 
imagine how transcription factors like p53 could contribute to this. Aged cells 
show loss of heterochromatin repressive histone marks and even nucleosome 
free regions of DNA, and the composition of core histones and histone variants 
change  (66, 69-71). Although the exact molecular mechanisms that lead to 
these changes are unknown, our epigenetic data from the allelic series suggests 
p53 may be involved. We know that at a local level, p53 directly interacts with 
chromatin modifying proteins (72). At the global level, less in known about how 
p53 enforces higher-order chromatin structure and nuclear architecture as a cell 
ages. In response to genotoxic stress, p53 unwinds chromatin to repair DNA 
lesions (73). Also, DNA damage triggers redistribution of chromatin remodelers 
like histone deacetylase SIRT1 (74). It is possible that too much p53 may directly 
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lead to abnormal patterns of histone modifications and changes in higher-order 
chromatin structure.  
Finally, we wished to determine what p53 transcripts generated in dp/+ 
MEFs. Genome wide transcriptome studies report global changes in transcription 
of aging cells due to defective splicing. Furthermore, numerous isoforms of p53 
have been detected, and naturally occurring isoforms of p53 are associated with 
an accelerated aging phenotype  (54). Therefore, we used a nested PCR 
approach to determine what isoforms of p53 are expressed in dp/+ MEFs. With 
this method, we detected two novel isoforms of the p53 transcript. By looking at 
what domains are modified we can speculate at the potential function of these 
isoforms.  
The translation of the p53 isoforms in dp/+ MEFs could potentially 
contribute to the observed phenotypes. If dp/+ p53 isoform 1 is translated, it may 
have enhanced stability compared to the full length isoform of p53. Translation of 
dp/+ p53 isoform 1 would generate an amino terminal truncated protein with a 
CTD that differs in from full length p53 in length and amino acid composition 
(Figure 3A). Both the carboxy and amino terminus of p53 are essential in 
regulating p53 stability by Mdm2. The stability of p53 occurs through the binding 
of Mdm2 in the transactivation domain which leads to the ubiquinitation of the 
CTD. If dp/+ p53 isoform 1 maintains the ability to interact with full length p53 in a 
tetramer, it could prevent Mdm2 mediated degradation.  
The expression of the isoforms could also alter the cellular localization of 
p53. The alternative splicing of exon 6 to 11 of dp/+ p53 isoform 2 would result in 
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a protein with an alterative carboxyl terminal domain. This isoform would also 
contain a truncated DNA binding domain and also lacks a NLS and 
oligomerization domain. The lack of NLS in the dp/+ p53 isoform 2 suggests 
cytoplasmic localization. Cytoplasmic p53 has the ability to interact with actin, 
and these interactions increase during cellular stress. 
Together, these findings that with increasing dose of p53 we see 
alterations in the extracellular matrix and nuclear envelope leads us to ponder 
the role of p53 as a sensor of mechanical stress. The cytoskeleton is coupled to 
the nuclear envelope and chromatin to provide a link for the transmission of 
mechanical signals in response to changes in the extracellular matrix (75). 
Mechanical forces can even directly regulate gene expression directly by altering 
the transport of transcription factors into the nucleus. Furthermore, nuclear 
envelope proteins, such as lamin A, bind to transcription factors. Since there is 
an interconnection between these structural proteins (76, 77), any forces that are 
transferred through these components may potentially directly alter gene 
expression (78, 79). 
Interestingly, transcriptional programs which demonstrate mechanical 
stress mediated control of transcription are linked with p53 activity. Increasing 
evidence demonstrates that mechanical control of transcription in involved in 
maintenance of pluripotency, cell fate determination, pattern formation and 
organogenesis  (75). Decades of research suggest p53 is intricately involved in 
these functions. Thus, a more complete understanding of how p53 could act as a 
mechanosensitive sensor and transcriptional programs induced under its control 
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may contribute to basic research in fields such as tissue engineering and 
regenerative medicine. 
Each study has limitations. One central caveat of this study stems from 
the use of the dp/+ allele. The dp/+ allele encompasses a 4.3 Mb region on 
mouse chromosome 4 which is syntenous to human 1p36. Although 
spontaneous somatic deletions have been observed in numerous types of 
cancers, to our knowledge no duplication of this locus exists. Thus, the allele we 
generated is artificial, and the consequences of this genetic aberration in humans 
is unknown. Furthermore, we do not have a clear understand of what genes in 
this locus contribute to the observed phenotypes. We must further address how 
the dp/+ allele fully contributes to the activation of p53. Bagchi et al. 
demonstrated that a key gene which contributes to the cancer phenotype when 
deleted is Chd5 (56). This chromatin remodeling protein is upstream of p53, and 
it modulates its expression through the p16/p19 pathway. Currently, the role of 
Chd5 in progeroid syndromes remains unexplored. 
A recent study hints at a Chd5-p53 connection between chromatin 
reorganization during cellular senescence (80). Using a cutting edge proteomics 
approach, Liu et al. measured the influx of proteins to the nucleolus upon 
induction of senescence. Similar to the nuclear envelope, the nucleolus is 
associated with morphological changes during aging. Interestingly, cellular 
senescence was associated with an influx of some Chd family members, 
including Chd5, and extensive chromatin re-organization of the nucleolus was 
observed. ARF, as well as other p53 binding proteins localized to the nucleolus, 
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suggesting a compartmentalization of p53 and this chromatin remodeling family 
during cellular senescence. Therefore, an investigation of how the genes of the 
dp/+ allele contribute to enhanced p53 activity is warranted. This may provide 
new insight as to how p53 contributes to chromatin structure globally.   
Studying the pathogenesis of age-related diseases is of major importance 
in a society with growing elderly population, and identifying an appropriate model 
system remains a challenge for the research community. The development of 
animal models for human disease aids our understanding of the underlying 
mechanisms that contribute to disease. This mechanistic insight is invaluable, 
because it enables the development of preventative and therapeutic strategies to 
combat disease. Ideally, we wish to a disease state in humans, however studies 
involving humans are often not feasible due the sample size necessary to 
overcome genetic and environmental variables or length of the lifespan. Thus, 
the use of animal models, such as genetically modified mouse models, with 
controlled genetic backgrounds and environment conditions are essential tools 
for basic research in the field of aging. This allelic series of p53 may be a 
powerful tool in elucidating mechanisms which contribute to age related diseases 
such as musculoskeletal degeneration as well as fundamental biological 
concepts pertaining to the how the spatial organization of the nucleus influences 
gene expression. The characterization of this model provides a foundation on 
which future work on the role of p53 in organismal aging can be built.   
 
 
 52 
 
Materials and Methods 
Cell Culture 
MEFs were derived from 12.5 dpc embryos with a mixed B6/129 background. 
The embryos were homogenized and plated on 10 cm tissue culture dishes. 
When cells reached confluency, they were passaged on three 10 cm dishes (p1), 
then frozen down into three vials per plate. The p1 vials of MEFs were thawed 
and the cells were expanded to passage 3 for experimental use. All experiments 
were conducted with early passage cells (p3-p6). MEFs were cultured in DMEM 
supplemented with 10% FBS and penicillin-streptomycin (100 units/ml).  
Microscopy 
Immunoflourence was performed according to Spector and Smith using the 
abcam lamin A/C and H3K9me3 antibody (Abcam) Cells were imaged at 40x 
magnification with the delta vision or transmission electron microscopy. 
 
Statistical Analysis 
Statistical analyses were performed using Microsoft Excel and Prism. The 
differences between two samples were analyzed using Student’s t test. The 
comparison of survival between mice shown in the Kaplan-Meier survival curves 
was performed using the Log Rank test. 
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Western Blot  
Protein was harvested with SDS sample buffer, run on 10% SDS-polyacrylamide 
gels, and transferred to a PVDF membrane overnight at 20 V. The membranes 
were blocked with 5% milk in TBS-T, incubated with the primary antibodies and 
secondary antibodies diluted in 5% milk in TBS-T. For a loading control GAPDH 
Cell Signaling Technology (14C10, #2118) was used at a concentration of 
1:2,000. 
 
Nested RT PCR and cDNA Library Generation 
RNA was isolated from MEFs three dp/+ and +/+ mice using Qiagen’s RNeasy 
Mini kit according to the manufacturer’s instructions.  The RNA was run on a 2% 
agarose gel to check the integrity, and treated with DNaseI (Invitrogen) before 
cDNA synthesis.  cDNA was synthesized with Promega’s GoScript Reverse 
Transcription System. Transcripts of p53 were amplified from +/+ and dp/+ cDNA 
with the following primers in table 1. PCR products were purified from agarose 
gels using Wizard SV Gel and PCR Clean-Up System according to 
manufacturers instructions and cloned into TOPO pcDNA3.1 vector.  Clones 
were sequenced with the CMV forward primer provided with the TOPO TA 
Cloning kit. 
 
Bioinfomatics Analysis 
The full length p53 nucleotide and protein sequences were retrieved from NCBI 
(Accession number NM 011649), and the domains of the protein were 
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determined with Uniprot. NCBI’s BLAST was used to align transcript and protein 
sequences, and SIB’s ExPASy was used for the translation of the DNA 
sequences to a protein sequences.  
 
Sequences  
 
Nucleotide sequence of full length p53  
TTTCCCCTCCCACGTGCTCACCCTGGCTAAAGTTCTGTAGCTTCAGTTCATT
GGGACCATCCTGGCTGTAGGTAGCGACTACAGTTAGGGGGCACCTAGCATT
CAGGCCCTCATCCTCCTCCTTCCCAGCAGGGTGTCACGCTTCTCCGAAGAC
TGGATGACTGCCATGGAGGAGTCACAGTCGGATATCAGCCTCGAGCTCCCT
CTGAGCCAGGAGACATTTTCAGGCTTATGGAAACTACTTCCTCCAGAAGATA
TCCTGCCATCACCTCACTGCATGGACGATCTGTTGCTGCCCCAGGATGTTG
AGGAGTTTTTTGAAGGCCCAAGTGAAGCCCTCCGAGTGTCAGGAGCTCCTG
CAGCACAGGACCCTGTCACCGAGACCCCTGGGCCAGTGGCCCCTGCCCCA
GCCACTCCATGGCCCCTGTCATCTTTTGTCCCTTCTCAAAAAACTTACCAGG
GCAACTATGGCTTCCACCTGGGCTTCCTGCAGTCTGGGACAGCCAAGTCTG
TTATGTGCACGTACTCTCCTCCCCTCAATAAGCTATTCTGCCAGCTGGCGAA
GACGTGCCCTGTGCAGTTGTGGGTCAGCGCCACACCTCCAGCTGGGAGCC
GTGTCCGCGCCATGGCCATCTACAAGAAGTCACAGCACATGACGGAGGTC
GTGAGACGCTGCCCCCACCATGAGCGCTGCTCCGATGGTGATGGCCTGGC
TCCTCCCCAGCATCTTATCCGGGTGGAAGGAAATTTGTATCCCGAGTATCTG
GAAGACAGGCAGACTTTTCGCCACAGCGTGGTGGTACCTTATGAGCCACCC
GAGGCCGGCTCTGAGTATACCACCATCCACTACAAGTACATGTGTAATAGC
TCCTGCATGGGGGGCATGAACCGCCGACCTATCCTTACCATCATCACACTG
GAAGACTCCAGTGGGAACCTTCTGGGACGGGACAGCTTTGAGGTTCGTGTT
TGTGCCTGCCCTGGGAGAGACCGCCGTACAGAAGAAGAAAATTTCCGCAAA
AAGGAAGTCCTTTGCCCTGAACTGCCCCCAGGGAGCGCAAAGAGAGCGCT
GCCCACCTGCACAAGCGCCTCTCCCCCGCAAAAGAAAAAACCACTTGATGG
AGAGTATTTCACCCTCAAGATCCGCGGGCGTAAACGCTTCGAGATGTTCCG
GGAGCTGAATGAGGCCTTAGAGTTAAAGGATGCCCATGCTACAGAGGAGTC
TGGAGACAGCAGGGCTCACTCCAGCTACCTGAAGACCAAGAAGGGCCAGT
CTACTTCCCGCCATAAAAAAACAATGGTCAAGAAAGTGGGGCCTGACTCAG
ACTGACTGCCTCTGCATCCCGTCCCCATCACCAGCCTCCCCCTCTCCTTGC
TGTCTTATGACTTCAGGGCTGAGACACAATCCTCCCGGTCCCTTCTGCTGC
CTTTTTTACCTTGTAGCTAGGGCTCAGCCCCCTCTCTGAGTAGTGGTTCCTG
GCCCAAGTTGGGGAATAGGTTGATAGTTGTCAGGTCTCTGCTGGCCCAGCG
AAATTCTATCCAGCCAGTTGTTGGACCCTGGCACCTACAATGAAATCTCACC
CTACCCCACACCCTGTAAGATTCTATCTTGGGCCCTCATAGGGTCCATATCC
TCCAGGGCCTACTTTCCTTCCATTCTGCAAAGCCTGTCTGCATTTATCCACC
CCCCACCCTGTCTCCCTCTTTTTTTTTTTTTTACCCCTTTTTATATATCAATTT
CCTATTTTACAATAAAATTTTGTTATCACT 
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Nucleotide sequence of dp/+ p53 isoform 1 
GACAGCTTTGAGGTTCGTGTTTGTGCCTGCCCTGGGAGAGACCGCCGTACA
GAAGAAGAAAATTTCCGCAAAAAGGAAGTCCTTTGCCCTGAACTGCCCCCA
GGGAGCGCAAAGAGAGCGCTGCCCACCTGCACAAGCGCCTCTCCCCCGCA
AAAGAAAAAACCACTTGATGGAGAGTATTTCACCCTCAAGATCCGCGGGCG
TAAACGCTTCGAGATGTTCCGGGAGCTGAATGAGGCCTTAGAGTTAAAGGA
TGCCCATGCTACAGAGGAGTCTGGAGACAGCAGGGCTCACTCCAGCTACCT
GAAGACCAAGAAGGGCCAGTCTACTTCCCGCCATAAAAAAACAATGCACAA
TCCTCCCGGTCCCTTCTGCTGCCTTTTTTACCTTGTAGCTAGGGCTCAGCCC
CCTCTCTGAGTAGTGGTTCCTGGCCCAAGTTGGGGAATAGGTTGATAGTTG
TCAGGTCTCTGCTGGCCCAGCGAAATTCTATCCAGCCAGTTGTTGGACCCT
GGCACCTACAATGAAATCTCACCCTACCCCACACCCTGTAAGATTCTATCTT
GGGCCCTCATAGGGTCCATATCCTCCAGGGCCTACTTTCCTTCCATTCTGCA
AAGCCTGTCTGCATTTATCCACCCCCCACCCTGTCTCCCTCTTTTTTTTTTTT
TTACCCCTTTTTATATATCAATTTCCTATTTTACAATAAAATTTTGTTATCACT 
 
Nucleotide sequence of dp/+ p53 isoform 2 
CTGCCATGGAGGAGTCACAGTCGGATATCAGCCTCGAGCTCCCTCTGAGCC
AGGAGACATTTTCAGGCTTATGGAAACTACTTCCTCCAGAAGATATCCTGCC
ATCACCTCACTGCATGGACGATCTGTTGCTGCCCCAGGATGTTGAGGAGTT
TTTTGAAGGCCCAAGTGAAGCCCTCCGAGTGTCAGGAGCTCCTGCAGCACA
GGACCCTGTCACCGAGACCCCTGGGCCAGTGGCCCCTGCCCCAGCCACTC
CATGGCCCCTGTCATCTTTTGTCCCTTCTCAAAAAACTTACCAGGGCAACTA
TGGCTTCCACCTGGGCTTCCTGCAGTCTGGGACAGCCAAGTCTGTTATGTG
CACGTACTCTCCTCCCCTCAATAAGCTATTCTGCCAGCTGGCGAAGACGTG
CCCTGTGCAGTTGTGGGTCAGCGCCACACCTCCAGCTGGGAGCCGTGTCC
GCGCCATGGCCATCTACAAGAAGTCACAGCACATGACGGAGGTCGTGAGA
CGCTGCCCCCACCATGAGCGCTGCTCCGATGGTGATGGTAAGCCCTCAAC
ACCGCCTGTGGGGTTAGGACTGGCAGCCTCCCATCTCCCGGCTTCTGACTT
ATTCTTGCTCTTAGGCCTGGCTCCTCCCCAGCATCTTATCCCGGTCCCTTCT
GCTGCCTTTTTTACCTTGTAGCTAGGGCTCAGCCCCCTCTCTGAGTAGTGGT
TCCTGGCCCAAGTTGGGGAATAGGTTGATAGTTGTCACGTCTCTGCTGGGC
CCAGCGAAATTCTATCCAGCCAGTGTGGACCCTGGCACCTACAATGAAATC
TCACCCTACCCACCACCCTGTAGATTCTATCTGGGGCCCTCATAGGGTCATA
TCTCAGGGCTTACTTTCTCATAAGGCGATCAGCACACTGGCGCCGTACTAAT
GATCGAGCTCGTACCAGCTTGCGTACCATGTCATAGCTGTTCTGTGTGATCT
GTAATCGGTTCACAGTCTACAGACATCGTGATCGTGGA 
TATGTCGATAAACGT 
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Full length p53 exon nucleotide position 
p53 
Exon 
Nucleotide Position in 
Transcript (nt) 
Length of Exon 
(nt) 
Exon 1 1-157 157 
Exon 2 158-240 82 
Exon 3 241-262 21 
Exon 4 263-523 260 
Exon 5 524-707 183 
Exon 6 708-820 112 
Exon 7 821-930 109 
Exon 8 931-1067 136 
Exon 9 1068-1141 73 
Exon 10 1142-1248  106 
Exon 11 1249-1772 523 
 
dp/+-p53 isoform 1 exon nucleotide position  
p53 
Exon 
Nucleotides Length of Exon 
Exon 8i 950-1067 117 
Exon 9 1068-1141 73 
Exon 10 1142-1248  106 
Exon 11i 1249-1264, 1487-1772 300 
 
dp/+-p53 isoform 2 exon nucleotide position  
p53 
Exon 
Nucleotides Length of Exon 
Exon 1
  
1-157 157 
Exon 2 158-240 82 
Exon 3 241-262 21 
Exon 4 263-523 260 
Exon 5 524-707 183 
Exon 6i 708, +76, 709-735   106 
Exon 11i 1412-1772 360 
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Translation of full length p53 
F P S H V L T L A K V L Stop L Q F I G T I L A V G S D Y S Stop G A P S I Q A 
L I L L L P S R V S R F S E D W Met T A Met E E S Q S D I S L E L P L S Q E T 
F S G L W K L L P P E D I L P S P H C Met D D L L L P Q D V E E F F E G P S 
E A L R V S G A P A A Q D P V T E T P G P V A P A P A T P W P L S S F V P S 
Q K T Y Q G N Y G F H L G F L Q S G T A K S V Met C T Y S P P L N K L F C 
Q L A K T C P V Q L W V S A T P P A G S R V R A Met A I Y K K S Q H Met T 
E V V R R C P H H E R C S D G D G L A P P Q H L I R V E G N L Y P E Y L E D 
R Q T F R H S V V V P Y E P P E A G S E Y T T I H Y K Y Met C N S S C Met G 
G Met N R R P I L T I I T L E D S S G N L L G R D S F E V R V C A C P G R D 
R R T E E E N F R K K E V L C P E L P P G S A K R A L P T C T S A S P P Q K 
K K P L D G E Y F T L K I R G R K R F E Met F R E L N E A L E L K D A H A T 
E E S G D S R A H S S Y L K T K K G Q S T S R H K K T Met V K K V G P D S 
D Stop L P L H P V P I T S L P L S L L S Y D F R A E T Q S S R S L L L P F L P 
C S Stop G S A P S L S S G S W P K L G N R L I V V R S L L A Q R N S I Q P 
V V G P W H L Q Stop N L T L P H T L Stop D S I L G P H R V H I L Q G L L S 
F H S A K P V C I Y P P P T L S P S F F F F Y P F L Y I N F L F Y N K I L L S 
 
Translation of dp/+ p53 isoform 1 
D S F E V R V C A C P G R D R R T E E E N F R K K E V L C P E L P P G S A 
K R A L P T C T S A S P P Q K K K P L D G E Y F T L K I R G R K R F E Met F 
R E L N E A L E L K D A H A T E E S G D S R A H S S Y L K T K K G Q S T S R 
H K K T Met H N P P G P F C C L F Y L V A R A Q P P L Stop V V V P G P S W 
G I G Stop Stop L S G L C W P S E I L S S Q L L D P G T Y N E I S P Y P T P 
C K I L S W A L I G S I S S R A Y F P S I L Q S L S A F I H P P P C L P L F F F 
F T P F Y I S I S Y F T I K F C Y H 
 
Translation of dp/+ p53 isoform 2 
L Stop L Q F I G T I L A V G S D Y S Stop G A P S I Q A L I L L L P S R V S R 
F S E D W Met T A Met E E S Q S D I S L E L P L S Q E T F S G L W K L L P P 
E D I L P S P H C Met D D L L L P Q D V E E F F E G P S E A L R V S G A P A 
A Q D P V T E T P G P V A P A P A T P W P L S S F V P S Q K T Y Q G N Y G 
F H L G F L Q S G T A K S V Met C T Y S P P L N K L F C Q L A K T C P V Q L 
W V S A T P P A G S R V R A Met A I Y K K S Q H Met T E V V R R C P H H E 
R C S D G D G K P S T P P V G L G L A A S H L P A S D L F L L L G L A P P Q 
H L I P V P S A A F F T L Stop L G L S P L S E Stop W F L A Q V G E Stop V D 
S C H V S A G P S E I L S S Q C G P W H L Q Stop N L T L P T T L Stop I L S 
G A L I G S Y L R A Y F L I R R S A H W R R T N D R A R T S L R T Met S 
Stop L F C V I C N R F T V Y R H R D R G Y V D K R 
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Chapter 4: The Domestication of Endogenous Retroviruses by p53 to 
Mediate Cell Viability 
 
Introduction  
A substantial proportion of the mammalian genome is comprised of 
repetitive sequences.  Initial analyses of genome sequencing projects revealed 
that repetitive elements make up 30-50% of mammalian genomes  (25, 81), but 
recent computational analysis suggests that this may be a gross underestimate, 
demonstrating that 66-69% of the human genome may be repetitive in nature 
(82). The major sources of these repetitive sequences are transposons. 
Transposons are a universal feature of genomes; they are found in bacteria, 
archaea and eukarya which encompasses every domain of life (23). Sometimes 
referred to as ‘jumping genes’ or ‘mobile elements’, transposons are DNA 
sequences that insert themselves into new locations of the genome (28). 
Whereas the DNA transposons mobilize through a cut and paste mechanism, the 
retrotransposons copy and paste themselves via an RNA intermediate. Although 
transposons are broadly classified by their mode of mobilization, transposition 
remains under tight epigenetic repression to maintain the fidelity of the genome 
(83).  
Recent advances in transcriptome analysis illustrate differential 
expression of distinct families of transposons among different cell and tissue 
types in mice and humans, but the specific functions of these transcripts have yet 
to be revealed (25). Barbara McClintock hypothesized that stress activates the 
expression of transposable elements to generate genetic diversity.  Indeed, 
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numerous studies demonstrate the activation of transposons in response to 
various forms of stress from bacteria to humans (84).  Their transposition can 
dramatically alter the landscape of the genome by promoting epigenetic changes, 
generating genomic rearrangements, or by scattering alternative regulatory 
sequences adjacent to genes (85). Furthermore, transposons can add 
transcribed, as well as functional, sequences to a genome (86). 
The consequences of stress activation of transposons widely researched 
in bacteria, yeast, and plants however in mammals much remains unknown (28). 
In order to elucidate mammalian cell stress response mechanisms, this study 
attempted to determine which transposons are regulated by the universal stress 
sensor, p53. It was hypothesized that distinct transposons are transcriptionally 
regulated by p53.  To this end, the transcriptome analysis was performed using 
an analysis to enrich for highly abundant sequences in normal cells and cells that 
were genetically modified to carry a null allele for p53 by RNA Sequencing (RNA 
Seq). Here we report the identification of stress responsive endogenous 
retroviruses (ERVs) of the HTLV-1 like Heptad Repeat 1-Heptad Repeat 2 family. 
 
Results 
In order to better understand the transcriptional role of p53, we utilized 
RNA Seq of early passage Mouse Embryonic Fibroblast generated from 
littermates in order to compare wildtype p53 (p53+/+) to single copy (p53-/+) and 
homozygous null allele of p53 (p53-/-).  In parallel, traditional microarray 
experiments were also carried out to ensure our sequence processing pipeline 
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maintained data integrity. The array data comparing the p53+/+ to p53-/- state 
clearly identifies canonical p53 target genes whose transcript level changes 
when p53 is deleted. For example, Ccng1 (Cyclin G1), CCdkn1a (p21) levels are 
greatly decreased in the p53-/- MEFS. These canonical p53 target genes are 
upregulated in response to distinct stimuli such as genotoxic stress (44). In the 
RNA Seq data analyzed using Cuffdiff, we observe a loss of transcription of 
canonical p53 targets in the p53-/- MEFs. Statistical analyses of the array results 
identified over 50 genes and Cuffdiff analysis of the RNA Seq results identifies 
over 100 genes to be differentially expressed. 24 of these genes were identified 
by both methods. While not always significant, when a gene was present in both 
array and RNA Seq datasets the RNA Seq data showed changes of direction 
consistent with the array data. The RNA Seq further identified many genes that 
were not observed by array.    
 Next, we looked at the p53 transcript levels in the datasets. We observed 
that p53 was reduced by ~3 fold on the array and ~30 fold by sequencing. It is 
commonly known that for many genes array data underestimates the overall fold 
change. To systematically determine whether the transcriptional response was 
indicative of a decrease in p53, we submitted the responsive gene lists and their 
direction of change to IPA analyses. As expected, targets of p53 were highly 
significantly enriched in the datasets (Array 4.36e-13, RNA Seq-13). Additionally, 
the observed direction of change can be used to predict that Trp53 activity is 
significantly reduced in the p53-/- MEFs by Z-score (Figure 15) (Array -3, SEQ -
4N). These results indicate that our analyses methods are consistent between 
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methods and that more complete information can be obtained by further analysis 
of the sequencing data. 
Due to the fact that the RNA Seq summarization based on the Cuffdiff 
method requires genome annotation, we hypothesized that additional targets of 
p53 may exist that were not present within the current annotation. Furthermore, 
just as controlling the stringency of an interaction is essential to array 
hybridization, controlling the stringency of mapping is highly relevant to the 
analyses of RNA Seq data specifically when repetitive elements are the subject 
of study. To respond to these two concerns, we developed a strategy to utilize 
highly stringent mapping coupled with a method to identify differential 
transcription without regard to prior annotation using code originally designed to 
identify genomic locations overrepresented in a data set. We call this new 
bioinformatics tool Annotation Independent Transcriptome Assembly (AITA). The 
most overrepresented locations identified by AITA with a 5-fold cutoff included 
Cyclin G1, p21 and other p53 target genes (Table 3), indicating that our method 
would identify regions in a similar fashion as those identified using annotation 
(Figure 15). Intriguingly, additional regions were identified that were not 
annotated in the mm9 annotation in a similar fashion as Cyclin G1 and p21. 
Additionally these unclassified regions showed reduced expression in p53+/- 
MEFs (Figure 15).  
The chromosomal location to which this region of the genome maps 
contains many repetitive elements. By stitching together the 100 base pair reads, 
we narrowed down the localization of this transcriptional peak to a region 
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approximately 10 kb in length. BLAT analyses of the highly abundant 7560 bp 
sequence found at the chromosome 8 region identified 13 copies of the transcript 
to be present at ≥ 99.0% within the mouse genome with additional copies on 
almost every chromosome in mouse. This sequence contains open reading 
frames (ORFs) encoding for gag, pro-pol, and env proteins and is classified as a 
Long Terminal Repeat (LTR) Retrotransposon (Figure 16). Using Repbase, we 
identify this sequence as Mmergln-int (87). In order to validate the RNA Seq 
results for the chr8 region containing the LTR Retrotransposon we designed RT-
PCR primers to the gag and env regions. PCR products with the correct size are 
generated from cDNA from MEFS with p53 and are not found in libraries from M 
(Figure 4A). An additional retrovirus was observed on chromosome 2, however 
this transcript no longer contains ORFs. We also found p53 dependent 
expression of SINES (Table 4).   
Because p53 is stabilized in response to stress, and stabilization 
increased the levels of p21 and Cyclin G1 we hypothesized that stabilization of 
p53 would also lead to increases in the transcript level of Mmergln-int. Exposure 
to ultraviolet light resulted in an ~ 2 fold increase of the Mmergln-int transcript.  
Additionally, qRT-PCR results show that p53 is necessary for basal transcription 
and in the absence of p53 no increase in retrovirus is observed. (Figure 17). 
Previous work has identified a specific sequence, the p53 response 
element, in proximity to the transcriptional start site that is required for p53 
dependent transactivation (37). Therefore, we looked for the p53 response 
element within the LTR of Mmergln-int. A highly conserved p53 response 
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element resides within the LTR (Figure 18). To demonstrate that p53 directly 
interacts with the LTR we conducted chromatin immunoprecipitation with an 
antibody against p53 (Figure 18). As a control, we are clearly able to observe an 
interaction between p53 and the p21 and Bax promoter that is not present in the 
absence of p53. Likewise, in the retroviral sequence we are able to clearly see 
that p53 interacts directly with the response element in the retroviral LTR in 
p53+/+ MEFs, but not in p53-/- MEFs. 
In order to demonstrate that the LTR is sufficient to drive expression of 
Mmergln-int, we cloned the 430 bp LTR in front of a luciferase reporter plasmid. 
Transient transfection of the LTR reporter construct into p53+/+ MEFs cells leads 
to luciferase activity similar to a similar construct generated from the p21 
promoter.  Mutation of the p53 response element in the retroviral sequence 
abrogates the reporter activity in the retroviral reporter in a similar fashion to 
removal of the element in the p21 reporter. 
We have shown that p53 is necessary for the transcription of Mmergln-int 
in response to stress. To determine whether the Mmergln-int has a function in 
classic p53 responsive pathways, we investigated cell viability via a MTT assay. 
We generated cell lines with a stably integrated doxycycline inducible Mmergln-
int transgene or GFP (Figure 19). The overexpression of Mmergln-int leads to 
decreases in cell viability in p53+/+ MEFs (Figure 20). Since p53 stabilization 
increases Mmergln-int expression, we hypothesized that either 1) p53 would not 
be necessary for the decreases in cell viability indicative of a linear signaling 
mechanism activated by p53 or 2) p53 would be required for decreases in cell 
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viability, indicative of a feed forward interaction potentially leading to signal 
amplification. In p53 null MEFS, overexpression of Mmergln-int does not lead to 
the changes in cell viability observed in p53+/+ MEFs (20). 
Interestingly, upon overexpression of Mmergln-int we noticed the 
appearance of multinucleated cells which do not occur following overexpression 
of GFP (Figure 21). This lead us to wonder if full length ERV was responsible for 
the decrease in cell viability, or if the Gag, Pro-Pol or Env proteins are sufficient 
to recapitulate the decrease in cell viability. Whereas transient overexpression of 
the Gag, Pol, or a control vector did not result in any significant change, 
overexpression of only the Env protein led to also lead to a decrease in cell 
viability similar to the overexpression of full length Mmergln-int (Figure 21).   
Further examination of the retroviral Env protein shows that it is a member 
of the HTLV-1 like Heptad Repeat 1-Heptad Repeat 2 family based on the 
domains this protein contains. Using the Conserved Domain Database, we 
discovered that this family of proteins is highly conserved and is present in 
modern infectious viruses (Figure 22) and is also found in many vertebrate 
sequences (Figure 23) including humans  (88).  Interestingly, human ERVs are 
upregulated in many cancers and autoimmune diseases  (89).   
To determine whether p53-mediated upregulation in response to 
genotoxic stress is a conserved feature of other ERVs, we designed qRT-PCR 
primers to specifically recognize the intact open reading frames of the human 
ERV envelopes (Table 3). Following UV treatment of MCF7 cells, qRT-PCR 
results show an upregulation of envR, env1 and envW similar to what was 
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observed with by Mmergln-int. Other HERVS were not responsive > 1.5 fold. To 
show that protein levels increased with increases in transcript, western blots 
using an envW antibody show increased protein levels 8 and 24 hours after UV 
exposure relative to non-treated MCF7cells at the appropriate molecular weight.  
One difficulty which arises from studying repetitive elements is the 
difficulty distinguishing between highly similar sequences. Zebrafish have a 
single ERV, ZFERV which is limited to only a few copies in the genome. Also, 
this ERV is basally expressed only in the thymus and its mRNA can be visualized 
by in situ hybridization. To study the effect of genotoxic stress in the context of a 
tissue, we exposed 5 day old larva to UV and gamma irradiation (IR). We 
observed an increase in the intensity of the ZFERV probe in UV treated fish. We 
validated our findings by qRT-PCR by comparing expression levels of p53, p21 
and ZFERV following UV and IR exposure to the basal expression level. We 
observe an increase in the transcripts of p53, p21 and ZFERV (Figure 24).    
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Figure 15. AITA identifies a non-annotated transcript arising 
from chromosome 8 
(A) A highly expressed transcript is identified by AITA, blue bars 
represent sequencing reads 
(B) The expression of the transcript is lost in p53-/- MEFs, and 
demonstrates reduced expression in the p53+/+ state 
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Figure 16. Mmergln-int is a highly abundant LTR 
retrotransposon  
(A) MEFs and loss of expression in p53-/- MEFs is an ~ 8.4 kb 
LTR Retrotransposon named Mmergln-int. Mmergln-int is 
classified as an endogenous retrovirus and had retained open 
reading frames which encode for gag, pro-pol and env proteins  
(B) The non-annotated transcript is present on every 
chromosome in mouse 
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Figure 17. Mmergln-int is expressed in p53+/+ MEFs and 
transcriptionally upregulated in response to genotoxic 
stress 
(A) RT-PCR analysis of Mmergln-int transcription in p53+/+, and 
p53-/- MEFs 
(B) qRT-PCR analysis of Mmergln-int transcription in response to 
UV damage in p53+/+, and p53-/- MEFs 
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Figure 18. p53 regulates the expression of Mmergln-int by 
binding a p53 Response Element in the LTR 
(A) The LTR of Mmergln-int contains a p53 response element at 
nucleotide position 103-123 
(B) Chromatin immunoprecipitation with p53, H3 and IgG 
antibodies  
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Figure 19. An inducible system to study the function of Mmergln-int  
 
The expression of Mmergln-int or GFP is induced with doxycycline 
 
 71 
 
 
 
A 	 	 	 	 	 				B	
	
	
	
	
	
	
	
	
	
	
	
	
	
C 	 	 	 	 	 				D	
Figure 20. Mmergln-int over expression results in a decrease in 
p53+/+ MEFs, but not p53-/- MEFs 
  
(A) Cell viability assay of p53+/+ MEFs induced to express GFP 
(B) Cell viability assay of p53+/+ MEFs induced to express Mmergln-int, 
Astrix represents p>0.05 
(C) Cell viability assay of p53-/- MEFs induced to express GFP 
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Figure 21. Mmergln-int overexpression results in cells fusion and the 
envelope is sufficient to induce a decrease in cell viability 
 
(A) Confocal microscopy of MEFs 48hr after Mmergln-int induction depicts cell 
membrane with β Catenin and nuclei with DAPI. Yellow arrows indicate multiple 
nuclei within cell membrane.  
(B) Cell viability assay after transient overexpression of Gag, Pol and Env    
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Figure 22. Conservation of the HTLV-1-like HR1 HR2 protein 
domain 
(A) HTLV-1-like HR1 HR2 protein domain is found in the 
present day viruses HTLV 1, HTLV 2, FLV, FEV and 
HoMuLV  
(B) The HTLV-1-like HR1 HR2 protein domain is endogenized 
in the genomes of multiple vertebrate species such as 
human, gorilla, chimpanzee, mouse, panda, marmoset, 
opossum, brushtail and zebrafinch 
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Figure 23. Human endogenous retroviruses are upregulated 
in response to genotoxic stress 
(A) Transcriptional levels of human endogenous retroviral 
envelopes in response to UV stress in Mcf7 cells 
(B) envW expression in Mcf7 cells after UV stress 
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Figure 24. ZFERV is transcriptionally upregulated in 
response to genotoxic stress 
(A) Sense and antisense probes generated to detect the 
envelope of ZFERV 
(B) qRT-PCR analysis of p53, p21 and ZFERV 
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Figure 25. Endogenous retroviruses may contribute to p53 mediated 
tumor suppression via cell fusion, enhancing p53 signaling through a 
feed forward signal amplification loop and other mechanisms. However 
aberrant expression for fusogenic endogenous retroviral envelopes may 
promote cancer.   
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Position Gene? 
Chr 11: 40562100-40572100 Ccng1 
Chr8: 124359000-124369000 No gene within 200bp 
Chr17: 29228000-29238000 Cdkn1 
Chr2: 7546700-75481700 No gene within 200bp 
Chr4: 136436200-136456200 C1qc 
Chr2: 165899700-165919700 Sulf2 
Chr18: 35021200-35026200 Egr1 
Chr2: 132692900-132712900 Lrrn4 
Chr 11: 69403100-69408100 p53 
 
 
  
Table 3. Differentially expressed genes identified by AITA     
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Name  Class 
 Mmergln-int   LTR Retrotransposon 
 MMVL30-int  LTR Retrotransposon 
B1 Mm SINE 
RSINE1 SINE 
B3 SINE 
B1 Mur1 SINE 
B1F2 SINE 
 
 
  
Table 4. AITA detects p53 dependent expression of repetitive elements 
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Name Location 
envR 7q21.2 
envW 7q21.2 
env1 19q13.41 
env2 19q13.41 
envFc1 Xq21.33 
envFRD 6p24.1 
envRb 3p24.3 
envH 3q26 
envH 2q24.3 
envK1 1q23.3 
envK2 12q14.1 
envT 19q13.11 
 
 
  
Table 5. Human endogenous retroviral envelopes for qRT-PCR screen 
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Discussion 
It is now appreciated that a large percent of the mammalian genome is 
comprised of repetitive elements, however the function of these sequences 
remains elusive. Most repetitive sequences are classified as transposons, mobile 
elements that are through to enhance the fitness of an organism by increasing 
genetic diversity in response to cellular stress (28). However, in humans and 
many other mammals, active mobilization of transposons is tightly restricted, and 
the expression of these sequences is concomitant with disease (89). The fact 
that transposons are no longer mobile in many species, but they remain 
preserved in the genomes of all species, suggests they have functions no longer 
dependent on mobilization. Using a genetic approach, we set out to identify 
stress responsive repetitive elements with the goal of learning more about how 
they contribute to the stress response of the HTLV-1 like Heptad Repeat 1-
Heptad Repeat 2 family.  
We developed a novel bioinformatics approach to analyze the expression 
of repetitive sequences, and we identified repetitive elements which were 
expressed only in cells with competent p53. Our approach, named Annotation 
Independent Transcriptome Assembly (AITA) is unlike traditional RNA Seq 
analysis tools. AITA allows us to easily play with the stringency of the transcript 
mapping of repetitive sequences. This methodology prevents misaligned 
sequences from being discarded from the transcriptome, which permits the 
analysis of their expression. By interrogating the transcriptomes of p53+/+ and 
p53-/- MEFs we identified the expression of distinct LTR Retrotransposons and 
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SINEs was lost in p53-/- MEFs. Interestingly, p53 dependent expression of 
SINEs has been previously reported. Furthermore, a bioinformatics analysis 
demonstrated that over 1,500 perfect p53 RE are found with in the LTRs of 
human ERV which strongly suggests a central role for p53 in their transcriptional 
regulation. 
We demonstrate that p53 regulates the expression of the ERV Mmergln-
int, by binding a conserved p53 response element in the LTR. The expression of 
Mmergln-int is detected in p53+/+ MEFs, and in response to genotoxic stress 
expression levels increase. The lack of Mmergln-int expression in p53-/- MEFs 
as well site directed mutagenesis experiments abrogating the function of the LTR 
by single mutations in the p53 regulatory sequence further indicate that p53 is 
the transcriptional regulator of this ERV.   
 After demonstrating the p53 regulates the expression of Mmergln-
int, we set out to address its potential function. The tumor suppressor, p53 is a 
key regulator of cell viability through the induction genes involved in processes 
such as apoptosis, necrosis or senescence. Thus, we wished to determine the 
influence of Mmergln-int expression on viability in comparison to a GFP control. 
We observed distinct changes in cell viability by MTT assay in p53+/+ MEFs, but 
not p53-/- MEFs, suggesting a feed forward mechanism which could enhance 
p53 function. When overexpressing Mmergln-int, we noticed a change in cellular 
morphology 24 hours upon inducing the expression of the ERV. Some cells 
formed multinucleated syncytia, a phenotype associated with viral transduction.  
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The observation of cellular fusion made us question what components of 
the ERV contribute to the decrease in cellular viability. By overexpressing the 
gag, pro-pol and env individually, we determined that overexpression of 
Mmergln-int’s envelope was sufficient to induce significant decreases in cell 
viability. Previously studies have observed that while the gag and pro-pol genes 
accumulate mutations that render them inactive, there is selective pressure to 
maintain the env suggesting it is functional (91).   
Interestingly, the envelope of Mmergln-int shares a striking degree of 
homology to the envelope of exogenous virus, HTLV-1. The envelopes of 
Mmergln-int and HTLV-1 are classified by its highly conserved Heptad Repeat 1-
Heptad Repeat 2 (HR1-HR2) domain (88). The HTLV-1 like Heptad Repeat 1-
Heptad Repeat 2 family encompasses exogenous viruses such as HTLV-1, 
HTLV -2, Moloney murine leukemia virus and simian T-cell lymphotropic virus 
(88). The molecular features of this protein domain subfamily include the HR1 
and HR2 coiled-coil forming helices which undergoes a conformation change to 
mediate cell fusion permitting viral entry (88).  
Notably, we identify members of the HTLV-1 like Heptad Repeat 1-Heptad 
Repeat 2 family endogenized in the genomes of many species, including 
humans. This lead is to hypothesize that decreases in cell viability upon 
expression of envelopes of the maybe be a conserved function of these 
endogenized viruses. We evaluated the expression levels in response to 
genotoxic stress. Our data indicate transcriptional upregulation of three human 
ERV envelopes. Although few antibodies against human ERVs, we can validate 
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upregulation of envW in Mcf7 cells. Our in silico analysis detects putative p53 
response elements residing in the regulatory region of envW.  
Interestingly, envW is one of the human ERVs for which a function is 
known. An alternative name for envW is Syncytin. The Syncytin gene encodes 
for a fusogenic membrane glycoprotein which is involved in trophoblast fusion in 
the placenta (92). Syncytin’s gag and pro-pol genes have undergone mutations 
which render them inactive, but the env remains preserved. The role of Syncytin 
expression in tissues besides the placenta remain poorly understood. Aberrant 
expression of Syncytin evokes an endoplasmic reticulum stress response as well 
as inflammation in the brain during multiple sclerosis (93). However, Syncytin has 
also been used to fight disease. It has been employed as an oncolytic agent 
which when overexpressed fuses cells to shrink tumors in vivo through the 
induction of apoptosis (94). 
This leads us to ponder the implications of ERV envelope expression in 
response to cellular stress. On one hand, stress signals which activate p53 may 
lead to upregulation of fusogenic ERV envelopes which promote the elimination 
of damaged cells. We hypothesize this mechanism may be driven by cellular 
fusion as well as the unknown mechanisms which enhance p53’s downstream 
pathways. On the other hand, abberent expression of fusogenic ERV envelopes 
may promote cancer. Multinucleated cells are hallmark of human cancer and 
have even been established as a prognostic factor to evaluate cancer initiation 
and progression (95, 96). An extensive body of work in the cancer field 
convincingly shows that multinucleated cells are the precursor to chromosomal 
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instability and aneuploidy, known drivers of cancer progression (97). It is even 
hypothesized that cellular fusion is the origin of cancer stem cells (98). Thus, 
future studies with to elucidate the physiological consequences of ERV 
expression in response to stress are warranted.  
 
Materials and Methods 
Cell Culture 
MEFs were derived from 12.5 dpc embryos with a mixed B6/129 background. 
The embryos were homogenized and plated on 10 cm tissue culture dishes. 
When cells reached confluency, they were passaged on three 10 cm dishes (p1), 
then frozen down into three vials per plate. The p1 vials of MEFs were thawed 
and the cells were expanded to passage 3 for experimental use. All experiments 
were conducted with early passage cells (p3-p6).  MEFs were cultured in DMEM 
supplemented with 10% FBS and penicillin-streptomycin (100 units/ml).  MCF 7 
cells were cultured in DMEM supplemented with 10% FBS, penicillin-
streptomycin (100 units/ml) and insulin (0.01 mg/ml). In induce cellular stress, 
cells were exposed to UV light (50 J/m2) or doxorubicin (50 mg/ml).  
MEFs were transiently transfected using Invitrogen’s Neon Transfection System 
or Promega’s FuGENE HD transfection reagent. Unsing the Neon Transfection 
System, MEFs were pulsed once with a pulse voltage of 1,350 V and pulse width 
of 30 ms at a density of 5x 106/ ml cells. To generate stable cell lines, MEFs were 
selected with puromycin. The expression of the tet-on constructs was induced 
using 50 ng/ml of doxycycline. 
 
Generation of Constructs 
Mmergln-int was PCR amplified from BAC RP23-8H9 using Takara’s LA TAQ 
DNA Polymerase and the following primers:  
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Mmergln int F:GGTTCCAATGCGCATTTGGAGGTCCCAGCGAGAT  
Mmergln int R: GGTTCCAAACTAGTTTCCCCTCTTCTTCTGTTTAGAC.  
Thermocycler conditions 94º 1 min, 94º 30 sec/58º 1 min/ 72º 9 min for 30 cycles/ 
72º 10 min. were used.  
 
The gag, pol and env were PCR amplified from BAC RP23-8H9 using Takara’s 
LA TAQ DNA Polymerase and the following primers:  
Pol F: GGTTCCAAAAGCTTATGCCTTTATTGGGGAGAGACTT,  
Pol R: GGTTCCAAGCGGCCGCTCATTGAGTACCTCCCACGTTTG  
Env F:GGTTCCAAAAGCTTATGATGAGTGGACTTTGGAGAA 
Env R: GGTTCCAAGCGGCCGCTTAGAGGTCGGTGTCCCTTAAC 
Gag F: GGTTCCAAAAGCTTATGGGACAGACCGTGTCTACTC 
Gag R: GGTTCCAAGCGGCCGCTAGTCTTCATCTTCTCCAAGAG 
The following thermocycler conditions were used for to amplify the pol gene: 94º 
1 min, 94º 30 sec/58º 1 min/ 72º 3 min 30 sec for 30 cycles/ 72º 10 min. The gag 
and env genes were amplified with the following conditions: : 94º 1 min, 94º 30 
sec/58º 1 min/ 72º 2 min for 30 cycles/ 72º 10 min. The PCR products were 
purified from an agarose gel using Wizard SV Gel and PCR Clean-Up System 
cloned into Invitrogen’s pcDNA 3.1(+) expression vector.   
  
Cell Viability 
In order to determine cell viability, cells were seeded in a 96 well tissue culture 
dish at a concentration of x cells/well. Cell viability was measured using 
Promega’s CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS).  
Measurements were taken at 12 hr, 36 hr, 60 and 84 hr after plating the cells. 
The MTT reagent was incubated at incubation at 37ºC, and the absorbance was 
measured with a microplate reader at 490 nm and 650 nm.  
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Transcriptome Analysis 
RNA was isolated from cells and tissues using Qiagen’s RNeasy Mini kit 
according to the manufacturer’s instructions, and treated with DNase I 
(Invitrogen) before cDNA synthesis.  
To detect the transcript of Mmergln cDNA was synthesized using Promega’s 
GoScript Reverse Transcription System.  Multiple PCR primers were designed to 
span the transcript of Mmergln-int.  The following primer pairs were used for RT 
PCR:   
GGACCAA GGA GAC CCAGAGAAG Ch8 Fi 
CCCGTG TCAAC TAGAAAGTC Ch8 Ri 
TCCGAGCCAATAACCCACAGG Ch8 Fii 
TTTAGCAGAGGCCCGATACC Ch8 Rii 
CCACGCATCCCACGTTAAGAG Ch8 Fiii 
AGGCCACCAAGTCCACAGAG Ch8 Riii 
CCAATTACTTTAACCCTGGCTGCCh8 Fiv 
GTCGCTAGGTCTTCATTGACAGCh8 Riv 
 
Promega’s GoTaq was used to amplify the cDNA.  The following thermocycler 
conditions were used to amplify the transcript of Mmergln-int: 95°C 2 min/95°C 
30 sec, 54° C 15 sec, 72°C 15 sec  for 22 cycles/72°C 5 min.  Beta Actin loading 
control was run with the previous thermocycler conditions PCR products were 
run of 2% TBE agarose gels.    
    
Real time quantitative PCR primers were designed to specifically detect to the 
envelope genes with a complete ORF. Primer sequences were designed using 
NCBI’s Primer Blast or taken from (90) RNA was extracted from cells with 
Qiagen’s RNeasy Mini kit according to the manufacturer’s instructions. cDNA 
was synthesized using Promega’s GoScript Reverse Transcription System. Real 
time quantitative PCR was performed using 25 µl of Promega’s GoTaq qPCR 
Master Mix. The data was collected with the Eppendorf Realplex 2.2 
Thermocycler  with the following program: 50°C 2 min, 95°C 10 min, 40x 95°C 15 
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sec/ 60°C 1 min, 95°C 15 sec, 60°C 15 sec, increase to 95°C over 20 min for 
melting curve analysis.   
 
Beta actin or GAPDH was used as an internal control to calculate differences in 
the amount of total RNA added in each individual reaction. Experiments with 
variation of the internal control less than a factor of 1were considered valid.  A 
student’s T test was performed to determine statistical significance. A p-value of 
p=0.05 was considered significant.   
  
Primer sequences for internal controls :  
human GAPDH F: TGCACCACCAACTGCTTAGC 
human GAPDH R: GGCATGGACTGTGGTCATGAG 
murine beta actin F: GTGGTTTTGATTCTCCTGTGTGC  
murine beta actin R: GCCTTGTACCCATCAGGGA 
 
Promoter Assay  
The LTR of Mmergln-int PCR amplified from BAC RP 23-2D22 cloned into the 
promoterless pGL3 basic vector with the following primers:  
LTR F: GGTTCCAACTCGAGTGAAAGGAAATA 
LTR R: GGTTCCAAAAGCTTTGAAAGAACTCA.    
The p21 and p21 mutant constructs are described in [Genes Dev. 1995 Apr 
15;9(8):935-44.] Mutations to the Mmergln-LTR were generated using 
QuikChange II Site-Directed Mutagenesis Kit.  A deletion was made at 
bases104-123 with the following primers:  
del104-123 F: atagcagaacagaccaatcgcctccctagctc  
del104-123 R: gagctagggaggcgattggtctgttctgctat.  
A single cytosine to adenine transversion mutations were made with the following  
primers  
c107a F: agaacagaccaggaaatgcccgggcaagc 
c107a R: gcttgcccgggcatttcctggtctgttct  
c117a F: gacatgcccgggaaagcccatcgcc  
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c117a R: ggcgatgggctttcccgggcatgtc.   
Two cytosine to adenine transversion mutations were made with primers:  
c107a c117a F: acagaccaggaaatgcccgggaaagcccatcgc 
c107a c117a R: gcgatgggctttcccgggcatttcctggtctgt.   
To generate the single base substitutions the following thermocycler conditions 
were used: 95º C 30 sec/ 95º C 30 sec, 55º 1 min, 68º 5 min 30 sec for 16 cycles 
and 18 cycles to generate the deletion and double base substitutions. p53 +/+ 
and p53 -/- MEFs were plated in 48 well tissue culture plates at a density of 
3X104 per well.  MEFs were co-transfected with the 50 ng/ well of the pRL-TK 
Renilla and 200ng/ well of the pGL3 basic experimental constructs. Cells were 
lysed and luciferase activity was measured 48 hours post transfection using 
Promega’s Dual-Luciferase Reporter Assay System according to manufacturer’s 
instructions. 
(mutations were based off papers: Transcriptional control of human p53 
regulated genes (Levine, 2008) and Algorithm for prediction of tumor suppressor 
p53 affinity for binding sites in DNA (Veprintsev, 2008)  
 
Western Blots 
Protein was harvested with SDS sample buffer, run on 10% SDS-polyacrylamide 
gels, and transferred to a PVDF membrane overnight at 20 V. The membranes 
were blocked with 5% milk in TBS-T, incubated with the primary antibodies and 
secondary antibodies diluted in 5% milk in TBS-T. Protein was visualized using 
Genemate’s (check exact name) Chemiluminescent HRP substrate. The abcam 
anti-hERVantibody (ab71115) was used at a concentration of 1:1,000 to detect 
Syncytin 1 and anti-HERV-FRD (ab90733) was used at a concentration of 1:100 
to detect Syncytin 2 protein levels. For a loading control GAPDH Cell Signaling 
Technology (14C10, #2118) was used at a concentration of 1:2,000. 
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Chromatin Immunopercipitation 
Milipore’s Magna ChIP A - Chromatin Immunoprecipitation Kit was used 
according to manufactures instructions with a p53 antibody  (1C12, Mouse mAb 
#2524 Cell Signaling Technology) 
 
Primers to detect LTR: 
ChIP LTR Fi GCTGAGAACATAGCAGAACAGACC  
ChIP LTR Ri GCACCCAAGAATCACGAATAGAAC  
ChIP LTR Rii AACAGGAGACAGTGGATTCGACC  
 
Primers used as a positive control:  
p21-F chip: CCTTTCTATCAGCCCCAGAGGATACC 
p21-R chip: GGGACGTCCTTAATTATCTGG GGTC 
Bax-F chip: GATGTTGTAGCCACCGCGTACAGCC 
Bax-R chip: TTCATGGTAGAGAGCACTAAGGAGG 
 
Immunofluorescence and Microscopy 
Immunofluorescence was performed according to Spector, D.L. and H.C. Smith. 
1986. Exp. Cell Res. 163, 87-94.  Imaging was performed with a Zeiss Observer 
confocal microscope.  
 
Bioinfomatics 
mRNA expression analysis 
mRNA transcript levels were detected by hybridization to illumina bead arrays. 
Each dataset was separately assessed for signal quality, quantile normalized and 
then probe sets mapping to the same gene were averaged. 
 
RNA Seq 
The RNA integrity was verified by quantification with a Ribo Green Assay and by 
running the samples on an Agilent Nano chip. Samples with a RIN number of 8 
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or above were used for mRNA seq library preparation. To prepare the library, 
mRNA was purified and fragmented. Next, cDNA was generated, end repair was 
performed, the 3' ends were adenylated and the DNA fragments were ligated to 
adaptors.  Ligation products were purified from an agarose gel. The library was 
quantified and validated using an Agilent High Sensitivity chip, Pico Green assay 
and KAPA qPCR.  
The characterization of repetitive elements was performed using the Table 
Browser function of the UCSC Genome Browser, and the classification of the 
repetitive elements was determined using BLAT and the Repeat Masker function.  
Identification of sequences of homology of to Mmergln-int were identified using 
the BLAT feature of the UCSC Genome Browser. Open reading frames were 
determined using NCBI’s Open Reading Frame Finder. NCBI’s Conserved 
Domain Database was used to investigate protein domains.  
 
The consensus sequence of Mmergln-int   
tttggaggccccagcgagatctgcgtgacacccaggaaccccgaaggaccccttggaggtgcgtttgttt 
gtgtgagtcttgttatgttgtctgttgtctaagtgtctaagtgtggcactgctgaatttgtgtcttagtt 
tttcagttctgagattgtgggtttgagccccacctgtgttaccagttctggtattctgtattctggcagc 
tgccactgcgttccgtaaggaccctagtggctgtgggaagacgacgatctatttccccacaggctgcacc 
cttggaagacattccgagggagaccctggagtgcccggggtacggaacagtcaggaggacctggctgttg 
cctggcagagtgaagaagagtgagtgctcttcctgccagaggagtggagcggaatcccactccatcagag 
gtagcgtttggctggttgtgtaagtccagacgcagatgagtgtgcttggatgtcttagtattttccgtct 
ctgtcattgtgttgtgtttactcttattcttcactatgggacagaccgtgtctactcctttatctttgac 
taaggaccattggacggacattagggctagaggacaaaatttgtcagtaaaagtgaagaaaaagccatgg 
atgactttctgttcctcagaatggcctgtttttggagtaggttggccagcagaaggaactttttacttac 
ccaccataagggctgtgaaggccattgtttttcaggaagggccagggtcgcatccagaccaacaaccgta 
cttcatggtatgggaggacttggcacgctacccacccccgtgggttcacccattcctcccgcctctccac 
cctggcaccaagattctagccatccgagaaaatggtgagaaagagaaaccaaaaccaccgctcgggagag 
atgatgatcacagcacaccagtgatgaaaccccccaagatctatccagagattgaaaccccctgagtggc 
ccaacacccctcaacccccaccgtatgctccccagccccaaccttcagctccctcaggacccctgcctca 
ggccccggccggaggagggggtccctccacaggaacaaggagccggcgaggagtcacccctgaggggcct 
gcggattcaaccgtggcgctccccctcagggctattggggctccccctgccgatccaaatagtctacagc 
ccctacagtattggcctttttcctcttctgacctctataactggaaagctaatcaccccccttttttcag 
aaaaccctgcaggactcactgggttggttgaatcattaatgtattcacaccagccgacctgggatgactg 
ccagcagcttctgcagactctattcacaactgaggagagagagaggattctcctcgaggctcggaaaaat 
gtccaagacgaggctgggcgccctgtccaaactccagctgagatagatgaaggatttccgctaacccggc 
cccgatgggattataatacggcatcaggtagggaacgactgtccaattatcgccgggtcctagtggcggg 
tctcagaggtgctgcccggcagcccacgaatctggccaaggtaagagaggttatgcagggagcgactgag 
cccccctcagtcttccttgaaaggctcatggaggcttataggagatataccccattcgaccccacgtctg 
agggtcaaagggcctcagtaattatggccttcattggccagtcggctcctgacattaggaagaagttaca 
gcgaattgagggcttgcaggattacaccataagggatgtagttagagaggcagagaaagtgtatcatagg 
agagaaacagaagatgaaaagttagagagagagaaaagagagaaaagagaagatgaggataggagagaca 
ggaggcaagaaaaggttttgactaggatcctggctgcagtaggagaaagagataatggaagaagaggtag 
acagtcagggaacctgggagacaaaagacagcagggaccaaggagacccagagaaggcgggcagcgcctg 
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gagaggaaccaatgtgcatattgcaaggaaatgggccactggaagagcaactgtccggaaaaaaaaacaa 
gaggtaaaggtgctttctcttggagaagatgaagactagggggaacggggcttgacccacctccccgagc 
ctagggtaactttagaagtggaggggtcccctgtggactttctagttgacacgggagccgaattttcagt 
actcaaaacacctctaggaaaagtgaagaaaaatgaaaaaaccttggtgatcggggccacgggacaaaaa 
tcgtatccatggaccacatcccgagtagtagacatagggcgaaatcgagtaactcattcgtttctagtca 
ttccagagtgtcctattcctttattggggagagacttactaaccaagttaaaagcacaaataactttcac 
ctctcatcgaccggaggttttctggggaataaaagcgccccagactctagagctgtctttacaactaggg 
gaggaatatcgactttaccaaaataaagtaaagccccctgagggattacaggactggttgaatcgatacc 
ctcaggcatgggcagagacgggaggagtggggatggcaaaactggtccccccccgtggtgattgaactta 
agtccggggccacccctataggggtccgacaatatcccatgagcagagaagctcaagagggtatacgccc 
ccaaattaacaaactgctccaacaagggattttggtcccatgcaaatccccttggaacactcctctactt 
ccagtaaaaaaaccagggaccagtgactaccgtccagtacaggaccttagagaagtcaacaagagagttc 
aggacatacaccccacggtgccaaatccttataacctcctcagcaccttgccacctggtcggacatggta 
cacagtcctggatctcaaagacacttttttctgtttgaggttacaccccaacagccagcccttgttcgct 
ttcgaatggcgagactccgagagtggacaagccggacagctcacatggacgaggctgcctcagggattca 
agaactcgcccactttgttcgatgaagccctacaccgagatcttgctcttttccgagccaataacccaca 
ggtgactcttctgcaatatgtagatgacctgctcctagctgcagaaacacacgaggactgtgaaattggg 
acctaaaacctcctgggcgagttaggtaacctggggtatcgggcctctgctaaaaaggctcagttatgcc 
agatagaagtgacctacctaggatatgtcttgagagatagacaacggtggctcacagaagccagaaaaca 
agctgttatgcagatcccgaccccaaccactgctcgccaggtaagagagttcctggggaccgccgggttt 
tgcagactctggattcctggatttgccacactggcagctcccttgtatccactaaccaaagagaaagggg 
aatttacctggaccagagaacatcagctagcctttgaaactctcaaaaaggcactgctgtaggctccggc 
attggccctgccagatttaaacaaacctttcaccctatacattgatgaaagaaatggagtggcaagggga 
gtccttacccaggttttgggaccatggaagcgcccggtagcctacttatcaaagaaactggaccctgtgg 
ccagtggatggccctcctgcctgcgagcgatagcagccacggctgtgctagtaagagatgctgacaaact 
gactatgggccagaatgttactatagtggccccacactctcttgagagcatcatcaggcaaccactggac 
cgctggatgaccaacgcccgaatgacgcactaccagagcctattgctgacagagcgagtaagttttgcac 
ccccagccattctcaaccctgcctccttactacctgaggctgacgaggcccctgcacataagtgtgaaga 
aatactggcagaagagactggaatccggccagacctcacagaccaaccttcgccaggggcgatgacttgg 
ttcacagacggaagcagctttgtggtagaaggtaagcggagggctggggcagcagtagtggatggaaagt 
ctgtcatatgggccagcagtctgctggagggtacatcagctcaaaaagcagaactaatcgcattaattca 
agccttaaggctggcagaaggaagggctcttaatgtctatactgacagccggtacgcttttgccacggct 
catgttcacagagcaatataccgacaccgtggactgctgacgtctgccggcaaagatatcaaaaataaag 
aaggaattctcagcttattagaagctgttcatctgccccgtagggtggtaattttccattgcccaggaca 
ccagaagggaactgggcccgttgaaaagggaaatcaaatggcagaccaagaagctaaaaaagcagcccaa 
gggccaatgactctggtggtgagaacccaacagcccgctgctgaggaaataaataaaagaaccctcacag 
aagaagaggggcgagattacttagctaacatacaccatctgactcatttaggaactaaaaaattactaaa 
attggttagtaagtccccctattacattcctggattaaaaagaattgtggaagagatagtaaaaaactgc 
cgtgcttgtgcacttaccaacgctgggtctagcaggctccaggaaagaaaacgactgcgaggagacaggc 
ctggagcctactgggaaactgacttcactgaggtgaaaccggctaggtatggaaataaatatctcctagt 
ttttatagacaccttttcaggatgggtcaaagcattccccaccaagaaagaaacgactaatgtagtggtc 
aagaagatacttgaagaaatccttccccgttttgggatacctaaggtaatggggtcagacaacagacctg 
ccttcgtctcccaggtaagtcagggattggccagacaactggggacaaattggaaattacattgtgcata 
cagaccccagagttcaggacaggtagaaaggatgaacagaacgctaaaggagactctgactaaaatagcc 
ttagaatccggtggaagcgattggacagccattctcccttatgccttgttcagggttcagaatacacctg 
gaccccttggcctaactccatttgaattaatgtatggggcgcccccacccatttttatgaccgtaggtga 
taagaatcgcctggatgtgtctttctctcctccttctagtcttttggctcgattaaaagctctcgaaata 
gtaagaaaagaggtctgggaacagctaaaagaaacctatgttgctggtgacacacaggtgccacatcagt 
ttgaagtaggagacgcagtcctggtgaggagacaccgagcaggaaacctagaaccgaggtggaagggacc 
ctacttggtgctactgacaacgcccaccgcggtcaaagtggaaggaatccccacttgggtccacgcatcc 
cacgtcaagagagcaccccctggagtcagccatgatgagtggactttggagaagactactaatcctttta 
agttgcgcctgcttcgtaggagcgatcccaaaagacttcaacccccacagtcctgttcaacaaacgtggg 
aggtactcaatgaggagggtagggctgtatggacaatcgccgaggtacaccctctgtggacttggtggcc 
tgatcttttccctgacatctgtaagttggctataggagcccctcctggatgggacttggaggggtactct 
gacattcagagggcacctttaacaccccctccgtacgtagaaaaacatttgagagacccgtggggtggtt 
gctctaaccaaagggatagaagtatgcttcgaacccatcccttctatgtctgccccgggccccaccaaag 
tcagtccctcaatccaacgtgtggaggtaaggctgacttcttttgcaagagctggggttgtgagacttca 
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ggtacagcccgctggaagccctcctcgagctgggactatattagagtaacagccaactattccctagcat 
cttatgtacctggaggatttgacctagacgagtgtactgactggtgccatccgctccgtgtcactttcac 
tgaaccagggaagagagctctgggatggacaagagggtatacctggggtcttaggatttacaaggaaaga 
tatgatgagggattattgttcactatcagattaaaaatagagaccccttacaatcctttaggccccccaa 
ccaagttcacacccctcacccatacaattactcagcctactccagtgattgcggacccccttaatatggc 
cgctatcacccaacctcccactcctcaggtacctctaactattacccccacgattccttcaagacagagg 
atgtttaacctagtgagaggagccttttatgcccttaacagaactgatccaagcgctactgaggactgct 
ggctatgcctgtcctcgggtccgccttattatgaaggaatcgccttcaatggagatttcaacagaatcag 
cagccatacttcctgctcttggggaacaggacaaaaactgaccctgactgaagtatccgtgaggaatcca 
ggtctctgtataggcaccccaccttccactcacaaacacctatgcggacaaattcagtccatgtccagaa 
cagaagctaattactatcttgtaccttccccggttggatggtgggcttgcaatacaggacttactccctg 
tgtatcaactaaggtttttaattcatctcatgatttttgtgtcatgatacagctgttaccccacgtatat 
tatcaccctgcatccagtttagaagaaagctatgctggccggaggtcaaaaagagaaccaactactttaa 
ccctggctgcattcatgggaataggtatggcagtaggagtggggacgggagtgtcagctttgatagaagg 
aagacagggaattcagtctttgagggatgctgtcaatgaagacctagcggcaatagagaagtccattgac 
gctttaaaaaaatctttgacctccctgtctgaggtagttttgcagaacaggagaggtcttgatttgttgt 
tcctcaaggaaggaggactgtgtgctgcccttaaagaagagtgctgcttctatgcagatcatacaggaat 
agttagagactctatgcagaaactgagagaaaaattagagcgaaggaaaccggaacgggatgctcaacgg 
gggtggtttgagtcgtggtttgaatcacgaccatcttggataacttctttaatttccgctgtagccggac 
caatccttatgatatgcttagctttagttttcagcccttgtataataaatagaggaatggctttcatcca 
gagtaaaattgatacagtaaaactcatggttcttcaaaggcaatatcaacctatagttcaggtagatgaa 
gagttaggggacaccaatctctaaaattctatgattagaattagtctaaacagaagaagaggggaa 
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Chapter 5: Future Directions 
 
Endogenous Retroviruses: 
Cancer Initiation Markers and Inflammation Mediators? 
 
Triggering the immune system to attack regions of the body which are 
undergoing cellular transformation is the overarching goal of cancer 
immunotherapy. However, the earliest events that activate an immune response 
following oncogenic stress remain unknown. This knowledge would provide 
mechanistic insights into tumorigenesis with the potential to aid in the 
development of better cancer drugs. To eradicate cancer we ideally wish to 
target cells at the onset of oncogene activation and simultaneously prevent a 
cancer promoting milieu in the surrounding tissues. Thus, we wish to identify 
molecules which serve as early markers of cancer initiation that also promote 
unfavorable conditions in the surrounding tissues. These key mediators should 
exhibit two intrinsic features: 
1. in response to cellular stress, they should be upregulated at the protein 
level, and 
2. their upregulation should be associated with a distinct immune response in 
vivo.  
We have recently identified a molecule that may fit both of these criteria. We 
developed a genetically engineered mouse strain which harbors an allele that 
results in the constitutive activation of the universal stress sensor, p53. In this 
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model, we observe p53 dependent activation of inflammatory signaling pathways. 
This model led us to seek out the molecular connection between the p53 
signaling pathway and inflammation.  Interestingly, we discovered a murine 
endogenous retrovirus (ERV), Mmergln-int, whose expression is dependent on 
the activity of p53. p53 is a tumor suppressor that is upregulated in the early 
stages of many cancers, and subsequently mutated during malignant 
transformation. We found that envelope (env) of Mmergln-int is sufficient to 
reduce cell viability independent of the other viral components ex vivo. Mmergln-
int env is characterized by a domain that is found in human T-cell leukemia virus 
type 1, an oncogenic retrovirus that also causes chronic inflammation. We 
discovered this protein domain family is endogenized in the genomes of multiple 
vertebrates, including humans, potentially highlighting that these sequences are 
functional. Interestingly, in human cell lines cellular stress upregulate the 
expression of distinct ERV envelopes. With this taken together, we propose that 
Mmergln-int env and homologous human ERV (hERV) are the early transducers 
of cancer initiation events stress which activate an immune response during 
tumorigenesis. 
 
Hypothesis and Objectives: We hypothesize that ERVs are upregulated during 
cancer initiation, as a result of cellular senescence observed in premalignant 
lesions of many types of cancers. Furthermore, we hypothesize that the 
expression of ERV envelopes induces an immune response to promote the 
elimination of precancerous cells. Our objectives are to determine the role of p53 
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in modulating hERV expression human prostate cancer and to delineate the 
consequences of ERV envelope expression in modulating immune response.  
 
Specific Aim 1: Determine the role of p53 in inducing the expression of 
human ERV in prostate premalignant lesions and adenocarcinomas 
a) Determine the correlation between hERV transcript level and p53 status in 
prostate adenocarcinoma 
b) Determine if hERV transcript level is a marker of prostate premalignant 
lesions in prostate tissue and serum 
c) Develop monoclonal antibodies against hERV envelopes to evaluate 
protein expression levels in human prostate tissue and serum 
d) Investigate the effect of oncogene activation or loss of tumor suppression 
on hERV expression in human primary prostate fibroblasts   
 
Specific Aim 2: Determine the physiological effects of ERV envelope 
expression. 
a) Evaluate the effect of Mmergln-int env expression on tumor volume 
b) Determine the ability of Mmergln-int env to promote migration of immune 
cells to tumor in vivo 
c) Investigate the ability of hERV envelopes to promote migration of immune 
cells ex vivo 
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Significance: This research aims to elucidate the function poorly understood 
genomic elements that make up at least 8% of the human genome. It proposes 
to address undiscovered two aspects of tumorigenesis i.e. what key molecules 
contribute to cancer initiation and how do they contribute to the elimination of 
precancerous cells. The implications of these findings may contribute to 
improved diagnostics and therapeutics for cancer. 
 
SIGNIFICANCE 
Understanding how tumors form is essential to eradicate cancer. 
Therefore the proposed research attempts to address two major unknown 
questions regarding tumorigenesis, namely 1) what are the earliest molecular 
markers of cancer initiation and 2) how do these molecules interact with the 
immune system to promote elimination of precancerous lesions or support the 
expansion of tumor cells. The answers to these questions could lead to better 
therapeutic measures to detect, prevent and treat cancer. Our current 
immunotherapy strategies target antigens found in tumors not premalignant cells. 
Thus, identification of markers of cancer initiation, like human endogenous 
retroviral envelopes, could provide new therapeutic targets that allow for earlier 
medical interventions. The proposed research could lead to novel diagnostic 
procedures and the development of monoclonal antibodies for adjuvant therapies 
for prostate cancer. 
In addition to studying the molecular underpinnings of tumorigenesis, this 
proposal aims to investigate the function of a portion of the genome that is poorly 
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understood. Endogenous retroviruses are a class of repetitive elements that 
comprise at least 8% of the human genome (99). Despite the fact that these 
genetic elements make up such a substantial proportion of the human genome, 
their functions have remained elusive due to technical limitations in accurately 
detecting their expression. RNA Sequencing (RNA Seq) in combination with 
bioinformatics tools to analyze repetitive sequences will finally allow us to explore 
in what context these genomic loci are expressed. Using this approach, the 
proposed research aims to ascribe a function to endogenous retroviruses with 
respect to tumor suppression. 
  
APPROACH 
Preliminary Studies 
The molecular mechanism by which an organism responds to stress is 
highly conserved. Genes homologous to the universal stress sensor, p53 exists 
even in the genomes of early animals such as anemones and worms (100). 
Stressors, such as DNA damage or oncogene expression, lead to the 
stabilization of the p53 protein. p53 functions as a transcription factor to activate 
the expression of genes involved in processes which maintain the integrity of the 
genome like DNA repair, halting the cell cycle or apoptosis (43, 44, 101). One 
mainstay of cancer research is determining p53 target genes to better 
understand its function as a tumor suppressor. Although, loss of p53 is one of the 
most frequent genetic aberrations in human cancer, this is a typically a late stage 
event occurring often during the process of malignant transformation (101). One 
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mechanism by which p53 acts as a tumor suppressor is to induce cellular 
senescence. The expression of oncogenes such as Ras, Raf and Akt or 
inactivation of tumor supressors such as PTEN or NF1 enhance p53 activity to 
induce cellular senescence in vivo (102, 103). Thus, examining the physiological 
outcome of constitutively activated p53 may help us to discover the molecular 
hallmarks of a developing premalignant lesion.  
In order to determine the physiological consequences of the constitutive 
activation of p53, we took advantage of a mouse model containing a duplication 
(dp/+) of an allele that positively regulates p53 expression. Although the mice 
with the dp/+ allele die at birth due to extreme senescence and apoptosis (Figure 
26A), this phenotype is completely rescued in the absence of p53 (Figure 26B) 
(56, 104). To better understand the phenotype of excess p53, the transcriptome 
of dp/+ mouse embryonic fibroblasts (MEFs) compared to +/+ MEFs. 
Interestingly, chemokines associated with an NFkB mediated inflammatory 
response were the most significantly upregulated genes in dp/+ MEFs (Figure 
26C). We wished to validate this phenotype in vivo, however the dp/+ mice 
exhibit perinatal lethality on postnatal day 1. Therefore we generated dp/+ mice 
in which both p53 alleles were inactivated through the introduction of a stop 
cassette flanked with loxp sites in intron one of the p53 gene (dp/+, p53 lsl/lsl). 
These mice were further crossed to carry the Cre ERT2 recombinase under the 
Rosa26 promoter. This combination of alleles allowed us to turn on the 
expression of p53 body wide by the administration of tamoxifen. The reactivation 
of p53 p53 lsl/lsl mice resulted in no significant changes, however the dp/+, p53 
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lsl/lsl mice were moribund within weeks of receiving the tamoxifen injections. 
Histopathological analysis revealed inflammatory foci in adipose tissue and 
mesentery in dp/+, lsl/lsl mice demonstrating that constitutive activation of p53 
results in inflammation in vivo. 
 In the interest of gaining a more complete understanding of how p53 
contributes to the activation of an inflammatory response, we coupled RNA Seq 
with a novel data analysis tool, AITA that detects the expression of regions of the 
genome that for which no annotated exists (Annotation Independent 
Transcriptome Assembly). A substantial proportion of mammalian genomes are 
comprised of poorly or non-annotated repetitive sequences whose functions 
remain unknown. With repetitive elements make up 30-50% of mammalian 
genomes (25), and a recent computational analysis demonstrating that 66-69% 
of the human genome is repetitive in nature (105), it is likely these regions of the 
genome contain undiscovered functional sequences which contribute to p53 
mediated tumor suppression.       
Using AITA, we discovered an non-annotated transcript derived from a 
LTR retrotransposon named Mmergln-int whose expression was not detected in 
the absence of p53 (Figure 27C, D, E). Transposons are the major source of 
repetitive sequences in mammalian genomes, and it is hypothesized that stress 
activates their expression to enhance the fitness of an organism (26, 83). Indeed, 
numerous studies demonstrate the transposons are activated in response to 
various forms of stress from bacteria to humans (23-25, 82-84) and differential 
expression of distinct families of transposons has been reported among different 
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cell and tissue types (25). However the specific functions of these transcripts are 
yet to be revealed. Therefore, we wished to determine the role of Mmergln-int 
with respect to p53 function. We demonstrate that p53 regulates the expression 
of Mmergln-int by binding a highly conserved p53 response element within the 
LTR, and that the LTR is capable of driving the expression of a luciferase 
reporter in the presence of p53 (data not shown). We detect transcriptional 
upregulation of Mmergln-int in response to genotoxic stress in p53+/+ MEFS and 
confirm Mmergln-int is not expressed in p53-/- MEFs (Figure 27D).   
After showing that p53 regulates the expression of Mmergln-int, we 
investigated how its expression influences cell viability. Overexpression of 
Mmergln-int in leads to decreases in cell viability in p53+/+ MEFS, and the 
transient overexpression of the env is sufficient to induce this change in p53+/+ 
MEFs (Figure 28). A further examination of Mmergln-int’s env protein reveals that 
it is classified as member of the HTLV-1-like heptad repeat 1-heptad repeat 2 
protein domain family. This highly conserved domain is present in modern 
infectious viruses and is also found in endogenized in the genomes of many 
vertebrate species, including humans. We observe an ~2 fold upregulation of 
envR, env1, and envW transcripts in human MCF7 cells after UV exposure, a 
known agent to induce p53. Although very few antibodies exist to detect 
expression of human endogenous retroviruses, we were able to confirm that 
protein level of envW increases at 8 and 24 hours after UV exposure relative to 
non-treated MCF7cells (Figure 28).  
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Figure 26. Constitutive activation of p53 induces an 
inflammatory response 
(A) dp/+ mice exhibit high levels of p53 and p21 which results in 
perinatal lethality  
(B) Lethality is rescued in dp/+, p53-/- mice  
(C) Microarray analysis demonstrates inflammatory chemokines 
are transcriptionally upregulated in dp/+ MEFs  
(D) Inducing the expression of p53 in dp/+, p53 lsl/lsl 8 week old 
mice results in inflammation of adipose tissue and mesentery 
which is especially severe adjacent to the pancreas that is not 
observed in lsl/lsl mice.  Inflammatory foci are and abnormal 
fibroblastic like cells are present in dp/+ lsl/lsl mice. 
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Figure 27. Annotation Independent Transcriptome Assembly 
identifies Mmergln-int in dp/+ MEFs 
(A) AITA identifies a differentially expressed transcript in dp/+ 
MEFS which is non-annotated  
(B) The transcript encodes for Mmergln-int, an ERV which 
demonstrates p53 dependent expression  
(C) p53 binds the LTR of Mmergln-int similar to other p53 target 
genes Bax and p21  
(D) RT PCR confirms expression of Mmergln-in p53+/+ but p53-
/- MEFs  
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Figure 28. Envelopes homologous to HTLV-1 are 
endogenized in the genomes of multiple vertebrate species 
and some are stress responsive in humans 
  
(A) The HTLV 1-like HR1-HR2 domain was identified in human, 
gorilla, chimpanzee, bushtail, mouse panda, marmoset, 
opossum, and zebra finch. Amino acids are highlighted with 
different colors to depict conservation among organisms. The 
degree of conservation is illustrated by calculating the 
conservation, quality and consensus of the alignments (black 
and yellow bar graph) 
(B) envR, env1 and envW are transcriptionally upregulated in 
response to UV stress in human Mcf7 cells and 
(C) envW is upregulated at the protein level at 12 and 24 hr after 
UV exposure. 
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Figure 29. p53 activates the expression of ERV envelopes to 
promote the clearance of premalignant cells 
     
Our model proposes that in premalignant lesions endogenous 
retrovirus are upregulated in response to enhanced p53 activity. 
The expression of transmembrane ERV envelopes activates an 
immune response which may promote the elimination of 
precancerous cells.  
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Specific Aim 1: Determine the role of p53 in inducing the expression of 
hERV in prostate premalignant lesions and adenocarcinomas 
We will investigate the expression of human ERVs in prostate tissue, 
because of the high rate of prostate cancer in the male population and the severe 
limitations in current prostate cancer screening procedures. According to the 
American Cancer Society, approximately 1 in 6 men will be diagnosed with 
prostate cancer in their lifetime. The Center for Disease Control and Prevention 
declared prostate cancer to be the most common cancer among men of all races, 
and the second leading cause of cancer related deaths in men. Furthermore, 
since many men have no symptoms or very mild symptoms, such as difficult or 
frequent urination, screening procedures are imperative in preventing the 
development of life threatening forms of prostate cancer. Recently, the US 
Preventative Services Task Force (USPSTF) recommended that men of all ages 
should no longer be screened for prostate cancer, because the potential benefits 
of the current screening procedures do not outweigh the harm they cause (106). 
Prostate cancer screening based on Prostate Specific Antigen (PSA) levels 
prevents 0-1 prostate cancer deaths per year. In fact, the USPSTF found current 
diagnostic procedures to be harmful, since over 10% of men screened receive a 
false positive resulting in a biopsy with potential side effects including severe 
infection, bleeding, pain and anxiety. Furthermore, in the event that prostate 
cancer is accurately diagnosed at an early stage, no histological or molecular 
marker can predict is a premalignant lesion will progress to adenocarcinoma 
(106-109). Considering the side effects of prostate cancer treatment include 
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range from sexual dysfunction, bladder and bowel incontinence to death, it is 
essential to better define individuals who will develop life-threatening cancer 
(106). These findings highlight an extreme need for more basic science research 
to identify markers of cancer initiation and progression.  
We wish to study expression levels of hERVs in prostate tissue during 
cancer initiation and progression. We demonstrated that distinct human ERV 
envelopes are upregulated in human breast adenocarcinoma cell lines after 
induction of p53 (Figure 3B,C) and preliminary data show that in envFc1 and 
envFrd are upregulated in human LNCaP prostate adenocarcinoma cell lines in 
response to genotoxic stress. This finding is consistent with a report indicating 
that over 30% of human p53 binding sites reside in endogenous retroviral LTRs 
(110, 111) Therefore, we hypothesize that senescent cells, which are known to 
express high levels of p53, can also be distinguished by increased levels of ERV 
transcripts and proteins. Furthermore, we hypothesize that premalignant lesions, 
which are enriched with senescent cells due to the activation of oncogenes or 
loss of tumor suppressors (112, 113), express higher levels of ERVs than benign 
tissue. We speculate that the activation of human ERV expression may serve as 
a general marker of cancer initiation with diagnostic and therapeutic implications. 
We chose to focus first on prostate cancer not only because of dire need to 
develop better diagnostic procedures, but also due to distinct molecular 
hallmarks of the disease. Previous studies detect transcription of hERV-K (114) 
in prostate cancer tissue and antigen in serum of prostate cancer patients (115). 
Furthermore, one of the few known markers premalignant lesions of the prostate 
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are elevated p53 levels (106, 116). Though few genes which promote prostate 
cancer initiation have been discovered, aberrant expression of Myc and the 
PI3K/PTEN/AKT signaling pathway contribute to enhanced p53 expression (117-
122). Therefore, we propose:  
a) Determine the correlation between hERV transcript level and p53 status in 
prostate adenocarcinoma 
In order to establish if a correlation exists between human ERV 
expression and p53 expression, we will analyze publically available human 
prostate adenocarcinoma transcriptome data from The Cancer Genome Atlas. 
Using our novel AITA approach, we will determine if expression levels of hERV 
correlate with enhanced p53 activity. (see letter of collaboration, Sarver) 
b) Determine if hERV transcript level is a marker of prostate premalignant lesions 
in prostate tissue and serum 
Transcriptome analysis will be performed on de-identified, staged human 
prostate tissue and serum from urologist Dr. Badrinath Konety at the Masonic 
Cancer Center (see letter of collaboration, Konety). Biostatistical analysis 
projects that less than 10 samples per stage will be needed in order to obtain 
statically significant results. RNA and protein will be harvested from the tissue 
samples to compare the expression of level of hERV of staged, high-grade 
prostatic intraepithelial neoplasia (HGPIN, grade PIN2 or PIN3) and acinar-type 
adenocarcinoma respect to benign tissue. Protein will be harvested in RIPA 
buffer supplemented with protease inhibitors and will be stored for later analysis. 
RNA Seq will be used to analyze the transcriptome of tissue samples. Briefly, 
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RNA will be isolated from tissue with Qiagen’s RNeasy Minikit and from serum 
with miRNeasy Serum/Plasma kit. The RNA integrity is to be verified by 
quantification with a Ribo Green Assay and by running the samples on an Agilent 
Nano chip. Samples with a RIN number of 8 or above will be selected for RNA 
Seq library preparation. For library preparation, the mRNA will be purified and 
fragmented. Next, cDNA will be synthesized, ends repair, and the 3' ends will be 
adenylated for ligation to adaptors. The library will be quantified and validated 
using an Agilent High Sensitivity Chip, Pico Green assay and KAPA qPCR. 
Differential expression of p53 target genes and hERVs will be determined by 
bioinformatics analysis. We will use quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) to validate the expression levels of hERVs (90) and 
selected p53 target genes. We will determine if it is possible to detect expression 
of hERVs in serum by qRT-PCR. For hERV sequence analysis, the consensus 
sequences will be extracted from Repbase (87) and mapped to hg19 with the 
UCSC Genome Browser (123).     
c) Develop monoclonal antibodies against hERV envelopes to evaluate protein 
expression levels in human prostate tissue and serum  
To further investigate hERV expression levels in human prostate 
precancerous lesions and adenocarcinomas, we will produce antibodies against 
transcriptionally upregulated hERVs for further characterize expression levels as 
previously described (124). To generate the immunogen, the ERV env will be 
cloned into pcDNA3.3 vector and the recombinant protein will be harvested from 
CHO cells. Female white leghorn chickens will be immunized with 200 μg of the 
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recombinant protein bimonthly, and bled one a week post injection to evaluate 
antibody titer. To clone the variable gene rearrangements of the heavy (VH) and 
light (Vλ) chains of immunoglobulin, RNA will be isolated from the spleen of the 
chickens and reverse transcribed with PCR primers VH and Vλ primers. The size 
of the PCR products will be confirmed on an agarose gel, then isolated from the 
gel for overlap extension PCR to construct the single chain variable fragments 
(scFv). The overlap extension scFv PCRs will be purified from an agarose gel, 
restriction digested and ligated into the pComb3HSS vector. The library will be 
transformed into E. coli and supplemented with the VCSM13 helper phage. To 
establish scFv that bind the antigen with high affinity, the library will be panned 
several times. The phages which bind the immobilized antigen are eluted then re-
amplified up to 6 rounds, before analysis by western blot and flow cytometry. The 
most specific scFvs will expressed in E. coli and purified by metal chelate 
chromatography. The protein levels of p53, p16, p21 and the human ERVs will 
be evaluated in prostate premalignant lesions and prostate adenocarcinoma 
tissues and serum by western blot.   
d) Investigate the effect of oncogene activation or loss of tumor suppression on 
hERV expression in human primary prostate fibroblasts 
To better understand the molecular events which occur during prostate 
cancer initiation, we will overexpress oncogene HrasV12 and knockout tumor 
suppressor PTEN in primary human prostate epithelial cells. The HrasV12 
expression construct or GFP control will be transduced in prostate epithelial cells. 
Transcription activator-like effector nucleases (TALENs TAL2344, TAL2345) will 
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be used to delete the PTEN locus. (125) We will assay for markers of 
senescence p16 and p21 by western blot and senescence-associated β-
galactosidase expression. The expression of human ERV envelope transcripts 
will be determined by qRT-PCR (126).    
 
Outcomes, potential problems alternative approach 
 We expect to observe upregulation of hERV envelopes such as envFc1 
and envFRD at the transcript and protein level in premalignant lesions of the 
prostate but not in benign tissue samples. We expect this will correlate with the 
induction of the p53 target genes, and p53, p16 and p21 protein levels. 
Moreover, we predict that in prostate adenocarcinoma tissue we will see a 
decrease in hERV expression levels the associated with p53 loss of function. 
These findings would suggest that if an individual demonstrates a decrease in 
hERV expression level their cancer maybe progressing to a more advanced 
stage. Based on previous studies, we expect to detect hERV protein in the serum 
of patients (115, 127). Future studies could focus on the validation of hERVs as 
early cancer biomarkers. Additionally, we could determine if the monoclonal 
antibodies against hERVs can be used to target xenografted tumors derived from 
human prostate adenocarcinoma cells in vivo. 
In the event we are not able to observe activation of hERV expression in 
RNA Seq data from prostate tissue, we will choose an alternative cancers to 
generate a basis for further molecular analysis such as lung, liver or colon 
adenocarcinoma, breast ductal carcinoma in situ (DCIS) or pancreatic 
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intraepithelial lesions (PANIN 1,2,3). Premalignant lesions of these tissues are 
also characterized by senescence in vivo (102, 116). If there is a delay in 
obtaining an adequate number of samples or we need an alternative tissue type, 
we will obtain tissues from Bionet, the tissue procurement facility at the University 
of Minnesota (see letter of collaboration, Bouley). With over 20,000 samples, this 
facility serves as a centralized resource for de-identified, standardized, staged 
benign and malignant tissues from human patients for researchers across the 
Unites States. Finally, if it is not possible to detect human ERV expression in 
serum samples, but an increase in expression is seen in prostate premalignant 
lesions, we will use SELDI-TOF Mass Spectrometry and use prostate secretion 
for molecular analysis, because it is a less invasive source of prostate cells than 
needle biopsy (B. Konety, personal communication). 
 
Specific Aim 2: Determine the physiological effects of ERV envelope 
expression 
We identified stress responsive ERV envelopes in human and mouse that 
share a high degree of homology among to the human pathogenic virus, HTLV-1. 
Interestingly, previously studies observed that while the gag and pro-pol genes of 
ERVs accumulate mutations that render them inactive, there is selective 
pressure to maintain the env suggesting it is functional (91, 128). Although the 
precise mechanism by which these glycoproteins decrease cellular viability is yet 
to be uncovered, the upregulation of ERV envelopes is associated with the 
activation of p53 mediated cell death pathways. Furthermore, multiple studies 
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demonstrate that the expression of ERV correlates with disease states 
associated with inflammation. For example, aberrant expression of envW evokes 
an endoplasmic reticulum stress response as well as inflammation in the brain in 
MS patients (93). Furthermore, envW has even been employed as an oncolytic 
agent which when overexpressed shrinks tumors in vivo by induction of 
apoptosis  (94). Thus, the correlation between the expression of endogenous 
retroviral envelopes in response to cellular stress and the induction of cell death 
pathways suggests they may have tumor suppressive properties yet possess the 
ability to induce an immune response (Fig. 29). In order to understand the 
physiologically effects of ERV envelope expression, we aim to: 
 
a) Evaluate the effect of Mmergln-int env expression on tumor volume 
Our previous studies demonstrate that overexpression of Mmergln-int 
results in a decrease in cell viability. We hypothesize the ERV envelopes may 
contribute to p53 mediated tumor suppression and possess the ability to inhibit 
the growth of tumors in vivo. To test this hypothesis, we will generate cell lines in 
which the expression of Mmergln-int env or a GFP control can be induced. The 
envelope of Mmergln-int or GFP will be regulated under in a doxycycline 
inducible promoter with and contain IRES-luciferase reporter for in vivo imaging. 
We will stably integrate the constructs in Lewis lung carcinoma cells (LLC1), a 
cell line isolated from lung tumor of C57BL mouse which is tumorigenic in mice 
(129, 130). We will transplant 105 cells of with the doxycycline inducible Mmergln-
int env or GFP control LLC1 cells into the right suprascapular region 10 mice per 
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cell line. At 48 hours post injection, doxycycline will be administered (625mg/kg 
feed or 10 mg/ml gavage daily) (131). The tumor volume and metastasis will be 
determined by external caliper measurement and in vivo imaging of live mice as 
described by Jenkins et al (132).  
 
b) Determine the ability of Mmergln-int env to promote migration of immune cells 
to tumor in vivo 
We hypothesize that expression of ERV envelopes activates an immune 
response which contributes to the clearance of cells with enhanced p53 activity. 
We predict that the induction of Mmergln-int env expression will evoke an 
immune response in vivo. To determine this, we will assess the infiltration cells of 
T cells and polarized M1 and M2 macrophages of the 3 weeks post doxycycline 
induction, the mice will be euthanized, the tumor tissue will be harvested to 
determine the presence of immune cell infiltration by flow cytometry. Tumor 
tissues will be dissociated with collagenase, and stained with T cells by flow 
cytometry using anti–CD4-PE, anti–CD8-PerCP-Cy5.5, and anti–TCR-β and 
macrophages by anti-CD86 and anti-MCR1. 
 
c) Investigate the ability of hERV envelopes to promote migration of immune cells 
in vitro 
 The role of the immune system in cancer is seemly contradictory; whereas 
the innate and adaptive immune response contributes to recognizing and 
destroying cancer cells during the process of cancer immunosurveillance, the 
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inflammatory tumor microenvironment promotes tumorigenesis (133, 134). In 
order to better understand the general role of hERV envelopes, we wish to study 
their ability to promote migration of immune cells. Using the Conserved Domain 
Database (88), we determined that hERVs of the ENV1-like and Rb-like domain 
families contain CKS17 peptides in their envelopes. CKS17 domains suppress 
lymphocyte proliferation, induce changes in cytokine production, and suppress 
pathways involved in T cell activation  (135). Thus, it is possible that some hERV 
envelopes promote tumor clearance while other contribute to cancer progression. 
To determine the unique contributions of hERV envelopes we will test the ability 
of hERV promote T cell chemotaxis by in vitro cell migration assays (136). 
Briefly, we will harvest T cells from 6 mn old mice thymi and plate them in 
transwell chambers with 5μm chemotaxis inserts. The lower chamber will contain 
either medium harvested from cells transiently overexpressing a hERV from the 
HTLV-1-like, ENV1-like and Rb-like domain families. Medium with 1 μg/ml 
recombinant mouse CCL21 will used as a positive control. We will quantify the 
number of T cells by flow cytometry using anti–CD4-PE, anti–CD8-PerCP-Cy5.5, 
and anti–TCR-β. To obtain the percentage migration, the number of CD4-
positive/CD8-negative/TCR-βhi cells will be counted and divided by input 
number.  
 
Outcomes, potential problems alternative approach 
We hypothesize that the upregulation of ERV envelopes induce an 
immune response. We this would be apparent by the infiltration of macrophages, 
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lymphocytes, Natural Killer cells, neutrophils or dendritic cells in tumors upon 
induction of Mmergln-int env whereas fewer or a different class of immune cells 
would be detected in the tumors of the GFP expressing control cohorts. We 
would also expect a reduction in tumor burden and metastasis in mice with 
allografts expressing Mmergln-int compared to the GFP control. It is possible that 
we observe no significant difference between the experimental and control mice, 
which could be possibly attributed to the high tumorigenicity of the LLC1 cell line. 
This could mask significant reduction in tumor size, or the LLC1 transplantation 
may alone promote an inflammatory response despite the fact that syngenic cells 
are engrafted. In the event we do not detect differences in cancer progression or 
immune response, we will selectively induce the expression of Mmergln-int or 
GFP in the livers of FAH-/- mice. First, will retrofit the constructs outlined in part b 
into a Sleeping Beauty transposon gene delivery vector and add the fumaryl 
acetoacetate hydrolase (FAH) gene. The constructs will be delivered to 
hepatocytes by hydrodynamic tail vein injection and we would select for the 
integration of DNA by removing the NTBC, which supplements the FAH 
deficiency, from the drinking water. After induction with dox, we would harvest 
the liver and assess infiltration of immune cells. We suspect the ERV envelopes 
posses distinct features which contribute the paradoxical. With over 1,500 perfect 
p53 binding sites in the promoters of endogenous retroviruses in humans (110), it 
is intriguing to speculate about how the contribute to the stress response in the 
state of human disease.     
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